Gut microbe derived aromatic amino acid metabolites for detection and treatment of disease
By identifying and treating altered levels of gut-derived aromatic amino acid metabolites, the method effectively assesses CVD risk and reduces cardiovascular events through targeted modulation of the TMA/FMO3/TMAO pathway, enhancing cardiovascular health.
Patent Information
- Application Number
- PCT/US2024/030534
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-23
- Filing Date
- 2024-05-22
- Publication Date
- 2024-11-28
AI Technical Summary
Current methods for identifying and treating cardiovascular disease (CVD) lack precision in detecting gut-derived aromatic amino acid metabolites (GDAAMs) and effectively targeting the TMA/FMO3/TMAO pathway, leading to inadequate risk assessment and potential adverse side effects from CVD therapies.
Developing systems and methods to identify altered levels of specific GDAAMs in plasma, such as phenylacetyl glycine and tryptophan metabolites, and treating subjects with agents that inhibit the TMA/FMO3/TMAO pathway, including lipid-lowering agents and antimicrobials, to reduce cardiovascular disease risk.
This approach enables precise identification of CVD risk and personalized treatment strategies, potentially reducing adverse cardiac events and improving cardiovascular health by modulating gut microbiota metabolism.
Smart Images

Figure IMGF000023_0001 
Figure IMGF000023_0002 
Figure IMGF000024_0001
Abstract
Description
[0001] GUT MICROBE DERIVED AROMATIC AMINO ACID METABOLITES FOR DETECTION AND TREATMENT OF DISEASE
[0002] The present application claims priority to U.S. Provisional application serial number 63 / 503,780, filed May 23, 2023, which is herein incorporated by reference in its entirety.
[0003] STATEMENT REGARDING FEDERAL FUNDING
[0004] This invention was made with government support under grant number HL 147823 awarded by the National Institutes of Health. The government has certain rights in the invention.
[0005] FIELD OF THE INVENTION
[0006] The present invention relates to systems, kits, and methods for identifying subjects with increased or decreased levels (e.g., in plasma) of at least one gut derived aromatic amino acid metabolite (GDAAM), as well as methods of determining the risk of cardiovascular disease, or other diseases, based on such levels. In certain embodiments, the level of at least two of the GDAAMs is employed (e.g., 2, 3, 4 or more). In some embodiments, a subject with altered levels of at least one of the GDAAMs is treated with a CVD therapeutic (e.g., lipid lowering agent) or one that inhibits the TMA / FMO3 / TMAO pathway.
[0007] BACKGROUND
[0008] Cardiovascular disease (CVD) is the general term for heart and blood vessel diseases, including atherosclerosis, coronary heart disease, cerebrovascular disease, aorto-iliac disease, and peripheral vascular disease. Subjects with CVD may develop a number of complications, including, but not limited to, myocardial infarction, stroke, angina pectoris, transient ischemic attacks, congestive heart failure, aortic aneurysm and death. CVD accounts for one in every two deaths in the United States and is the number one killer disease. Thus, prevention of cardiovascular disease is an area of major public health importance.
[0009] A low-fat diet and exercise are recommended to prevent CVD. In addition, a number of therapeutic agents may be prescribed by medical professionals to those individuals who are known to be at risk of having CVD. These include lipid-lowering agents that reduce blood levels of cholesterol and trigy Icerides, agents that normalize blood pressure, agents, such as aspirin, or platelet ADP receptor antagonists that prevent activation of platelets and decrease vascular inflammation (e.g., clopidogrel and ticlopidine), and pleiotrophic agents such as peroxisome proliferator activated receptor (PPAR) agonists, with broad-ranging metabolic effects that reduce inflammation, promote insulin sensitization, improve vascular function, and correct lipid abnormalities. More aggressive therapy, such as administration of multiple medications or surgical intervention may be used in those individuals who are at high risk of having CVD. Since CVD therapies may have adverse side effects, it is desirable to have methods for identifying those individuals who are at risk, particularly those individuals who are at high risk of experiencing an adverse cardiac event near term.
[0010] SUMMARY OF THE INVENTION
[0011] The present invention relates to systems, kits, and methods for identifying subjects with increased or decreased levels (e.g., in plasma) of at least one gut derived aromatic amino acid metabolite (GDAAM), as well as methods of determining the risk of cardiovascular disease, or other diseases, based on such levels. In certain embodiments, the level of at least two of the GDAAMs is employed (e.g., 2, 3, 4 or more). In some embodiments, a subject with altered levels of at least one of the GDAAMs is treated with a CVD therapeutic (e.g., lipid lowering agent) or one that inhibits the TMA / FM03 / TMA0 pathway.
[0012] In some embodiments, provided herein are methods of performing an activity based on a level of a first and / or a second gut derived aromatic amino acid metabolite (GDAAM) in a sample from a subject comprising: a) determining, or receiving information regarding, the level of the first and / or second GDAAM in a sample from a subject, wherein the first GDAAM is selected from the following first group: phenylacetyl glycine, Phenylacetic acid, Hippuric acid, Phenylacryl glycine, p-Cresol glucuronide, 4-OH-Phenyllactic acid, 4- Ethylphenylsulfate, 4-OH-Benzoic acid, 4-OH-Hippuric acid, 2-OH-Hippuric acid, 3-OH- Hippuric acid, Indole glucuronide, 5-OH-indole-3-acetic acid, Indole-3 -acetyl glutamine, Serotonin, Indole-3 -acetic acid, Indole-3-lactic acid, and N-Acetyl-tryptophan, and wherein the second GDAAM is selected from the following second group: Tyrosine (Tyr), 2-OH- Benzoic acid, and Tryptophan (Trp); and b) identifying an increased level of the first GDAAM in the sample compared to a first corresponding control value and / or identifying a decreased level of the second GDAAM in the sample compared to a second corresponding control value, and performing at least one of the following activities: i) treating the subject with: A) an agent or procedure that inhibits the TMA / FM03 / TMA0 pathway, and / or B) a cardiovascular disease therapeutic, and / or C) an anti-thrombotic agent, and / or D) an antiplatelet agent, and / or E) an antibiotic or antimicrobial that reduces trimethylamine (TMA) production in the gut, and / or F) providing or prescribing a dietary intervention; ii) generating and / or transmitting a report that: A) displays the first and / or the second GDAAM level, and B) indicates that the subject is in need of the agent or procedure that inhibits the TMA / FM03 / TMA0 pathway, and / or the cardiovascular disease agent, and / or the antithrombotic agent, and / or the anti-platelet agent, and / or the antibiotic or antimicrobial agent, anti-obesity agent, anti-metabolic disease agent, and / or the diet; and iii) characterizing the subject as having a cardiovascular disease, or an elevated risk for cardiovascular disease, or an elevated risk for obesity, or an elevated risk for a metabolic disease, and / or elevated risk for a thrombotic event.
[0013] In certain embodiments, provided herein are methods of treatment comprising: a) identifying a subject as having: i) increased levels of a first gut derived aromatic amino acid metabolite (GDAAM) compared to a first corresponding control value, and / or ii) decreased levels of a second GDAAM compared to a second corresponding control value, wherein the first GDAAM is selected from the following first group: phenylacetyl glycine, Phenylacetic acid, Hippuric acid, Phenylacryl glycine, p-Cresol glucuronide, 4-OH-Phenyllactic acid, 4- Ethylphenylsulfate, 4-OH-Benzoic acid, 4-OH-Hippuric acid, 2-OH-Hippuric acid, 3-OH- Hippuric acid, Indole glucuronide, 5 -OH-indole-3 -acetic acid, Indole- 3 -acetyl glutamine, Serotonin, Indole-3 -acetic acid, Indole-3-lactic acid, and N-Acetyl-tryptophan, and wherein the second GDAAM is selected from the following second group: Tyrosine, 2-OH-Benzoic acid, and Tryptophan; and B) treating the subject with: i) an agent or procedure that inhibits the TMA / FM03 / TMA0 pathway, and / or ii) a cardiovascular disease therapeutic, and / or iii) an anti- thrombotic agent, and / or iv) an anti-platelet agent, and / or v) an antibiotic or antimicrobial that reduces the production in the gut of the first GDAAM, and / or vi) providing or prescribing a diet with reduced levels of carnitine, choline, and / or lecithin containing compounds; and / or vii) an anti-obesity agent; and / or viii) an metabolic disease agent.
[0014] In particular embodiments, the subject is a human, and / or wherein the identifying comprises receiving information regarding the subject as having: i) increased levels of a first GDAAM compared to a first corresponding control value, and / or ii) decreased levels of a second GDAAM compared to a second corresponding control value, and optionally wherein the receiving information comprises receiving a report, wherein the receiving the report is optionally via: 1) the mail system, 2) email, or 3) via a LAN of a hospital or clinic.
[0015] In some embodiments, provided herein are methods of detecting the level of a first and / or second gut derived aromatic amino acid metabolite (GDAAM) in a sample from a subject comprising: a) obtaining a sample, wherein the sample is from a human subject with cardiovascular disease; and b) treating the sample under conditions such that the first and / or second GDAAM level present in the sample is determined. In other embodiments, the level of the first and / or second GDAAM in the sample is determined by mass spectrometry. In particular embodiments, the sample is a plasma or serum sample In some embodiments, the identifying comprises identifying both the increased level of the first GDAAM, and a decreased level of the second GDAAM. In certain embodiments, the first GDAAM is phenylacetyl glutamine (PAGln) and the second GDAAM is Indole-3- propionic acid (I3P). In other embodiments, the methods further comprise: determining the level of an additional GDAAM that is different from the first or second GDAAM, wherein the additional marker is phenylacetyl glutamine or Indole-3 -propionic acid, or is selected from the first group or the second group, but does not include p-Cresol sulfate or Indoxyl sulfate. In additional embodiments, the identifying comprises identifying the increased level of the first GDAAM, or the decreased level of the second GDAAM, and further identifying the additional GDAAM as having: i) an increased level compared to a first additional control value if selected from the first group, or ii) having a decreased level compared to a second additional control value if selected from the second group. In further embodiments, wherein: i) the first GDAAM is PAGln, and the additional GDAAM is I3P; ii) the first GDAAM is PAGln, and the additional GDAAM is Trp; iii) the first GDAAM is PAGln, and the additional GDAAM is Tyr; iv) the first GDAAM is 4-OH-HA, and the additional GDAAM is 13P; v) the first GDAAM is 4-OH-HA, and the additional GDAAM is Trp; or vi) the first GDAAM is 4-OH-HA, and the additional GDAAM is Tyr.
[0016] In some embodiments, the identifying an increased level of the first GDAAM in the sample comprises identifying the level of the first GDAAM as at, or above, the 75% quartile range (or 70% or 65% or 60% quartile range); and / or wherein the identifying a decreased level of the second GDAAM in the sample comprises identifying the level of the second GDAAM as at or below the 25% quartile range (or 30% or 35% or 40% quartile range). In certain embodiments, the methods comprising detecting the level of a particular marker selected from: TMAO (trimethylamine-N-oxide), trimethyllysine, Crotonobetaine, gamma butyrobetaine, carnitine, choline, and betaine.
[0017] In other embodiments, identifying further comprises identifying an increased level in the particular marker compared to a corresponding particular control value. In additional embodiments, the subject has, or is suspected of having, a cardiovascular disease (or obesity or a metabolic disease). In some embodiments, the cardiovascular disease is selected from: coronary artery disease (CAD), peripheral artery disease (PAD), heart failure (HF), HF with preserved ejection fraction (HFpEF), HF with reduced ejection fraction (HFrEF), left ventricular systolic dysfunction, need for revascularization, need for CABG, need for angioplasty, need for stent, vascular aneurysm, abdominal aortic aneurysm, thoracic aortic aneurysm, arrhythmia, atrial fibrillation, ventricular fibrillation, ventricular tachycardia, acute coronary syndrome, NSTEMI and STEMI Stroke, transient ischemic attack (TIA), cardiovascular disease (CVD).
[0018] In particular embodiments, the subject is, or is suspected of being, at risk for a thrombotic event. In additional embodiments, the methods further comprise: determining the level of a further GDAAM that is different from the first or second GDAAM and different from the additional marker, wherein the further marker is phenylacetyl glutamine or p-Cresol sulfate, Indoxyl sulfate, or Indole-3 -propionic acid, or is selected from the first group or the second group. In some embodiments, the identifying comprises: A) identifying the increased level of the first GDAAM, or the decreased level of the second GDAAM, B) identifying the additional GDAAM as having: i) an increased level compared to a first additional control value if selected from the first group, or ii) having a decreased level compared to a second additional control value if selected from the second group, and C) identifying the further marker as having: i) an increased level compared to a first further control value if selected from the first group, or ii) having a decreased level compared to a second further control value if selected from the second group. In other embodiments, the methods further comprising detecting the level of a particular marker selected from: TMAO (trimethylamine- N-oxide), trimethyllysine, Crotonobetaine, gamma butyrobetaine, carnitine, choline, and betaine. In additional embodiments, the identifying further comprises identifying an increased level in the particular marker compared to a corresponding particular control value. In certain embodiments, the report further displays the corresponding control value for the first and / or second GDAAM.
[0019] In particular embodiments, the report comprises a paper report or an electronic report; and / or wherein the receiving information comprises receiving the report, wherein the receiving the report is optionally via: 1) the mail system, 2) email, or 3) via a LAN of a hospital or clinic. In further embodiments, the transmitting the report comprises: 1) mailing the reporting through the mail system, 2) emailing the report over the internet, or 3) sending the report through a local area network (LAN) or a hospital or clinic. In additional embodiments, the first and second corresponding control values are derived from samples from the general public or from a group known to not have cardiovascular disease or be at elevated risk for a thrombotic event.
[0020] In some embodiments, the cardiovascular disease therapeutic is a lipid lowering agent, and optionally wherein the lipid lowering agent comprises a statin. In additional embodiments, the cardiovascular disease therapeutic is selected from: i) atorvastatin, rosuvastatin, simvastatin, pravastatin, lovastatin, pitavastatin, bempadoic acid, ii) a PCSK9 inhibitor, wherein the PCSK9 inhibitor optionally comprises a anti-PCSK9 antisense or siRNA, or an anti-PCSK9 antibody, fragment thereof, or nanobody, iii) an apoB inhibitor, wherein the apoB inhibitor optionally comprises a anti-apoB antisense or siRNA, or an anti- apoB antibody, fragment thereof, or nanobody; or iv) lipoprotein a or apolipoprotein a.
[0021] In certain embodiments, the sample is selected from the group consisting of: a plasma sample, a serum sample, and a urine sample. In other embodiments, the determining comprises detecting the GDAAM with an analytical device selected from: a mass spectrometer, NMR spectrometer, and a UV / Vis spectrometer. In further embodiments, the agent or procedure that inhibits the TMA / FM03 / TMA0 pathway is selected from the group consisting of: i) a compound selected from CC136 and CC272; ii) acetylsalicylic acid with or without an enteric coating; iii) an acetylsalicylic acid derivative with or without an enteric coating; iv) compound CC270; v) a gut TMA lyase inhibitor; vi) fecal microbiota transplantation and / or synthetic polymicrobial feces transplantation, and / or gut bacteria spores; vii) delivery of acetylsalicylic acid or derivative thereof directly to the colon or cecum of the subject; viii) a probiotic or prebiotic that reduces production in the gut of the first GDAAM; ix) a TMA and / or TMAO sequestering agent; x) a TMA lyase inhibitor is selected from: a halomethyl choline, iodomethylcholine, fluoromethycholine, a halomethyl betaine, a halomethyl betaine salt, a halomethyl betaine amide, and a halomethyl dimethyl amino alcohol; xi) 3-(2,2,2-trimethylhydraziniumyl) propionate; and xii) a compound of any of Formulas I- III or V.
[0022] In some embodiments, the cardiovascular disease therapeutic, anti-obesity agent, and / or anti-metabolic disease agent is selected from: an ACE inhibitor, an angiotensin II receptor blocker (ARB), insulin, an amylinomimetic drug, an alpha-glucosidase inhibitor, a biguanide, a dopamine agonist, a DPP-4 inhibitor, a glucagon- like peptide, a meglitinide, a sodium glucose transporter (SGLT) 2 inhibitor, a sulfonylureas, Pioglitazone, cenicriviroc, Elafibranor, Ocaliva (obeticholic acid), Selonsertib, thiazolidinedione, Inclisirin, anti-apoB targeting drugs, Anti-LPa targeting drugs, anti ATP citrate lyase targeting (bempedoic acid) drugs, SGLT2 inhibitor, SGLT1 inhibitor, SGLT1 / 2 mixed inhibitors, and / or GLP1 agonists, a Beta Blocker, statin, PCSK9 inhibitor, ATP-citrate lyase inhibitor (bempedoic acid), SGLT2 inhibitors, GLP1 agonists, metformin, SGLT1 inhibitors, and mixed SGLT 1 / 2 inhibitors, inclisirin and ASO or siRNA to apoB. In other embodiments, the antibiotic is at least one antibiotic selected from the group consisting of: metronidazole, ciprofloxacin, neomycin, amoxicillin, and a broad spectrum antibiotic; and wherein the subject does not have an active infection.
[0023] In certain embodiments, the dietary intervention is selected from: with reduced protein, or Mediterranean diet, or diet low in red meat, or diet that avoids protein supplements, or diet high in whole grains and / or fiber and whole foods. In some embodiments, prescribing a dietary intervention is: i) with goal of lower cardiovascular or metabolic disease risks, ii) designed to improve health and wellbeing, and iii) designed to lose weight.
[0024] In additional embodiments, provided herein are systems and kits comprising: a) a report for a subject with cardiovascular disease, wherein the report indicates that the patient has: i) increased levels of a first gut derived aromatic amino acid metabolite (GDAAM) compared to a first corresponding control value, and / or ii) decreased levels of a second gut derived aromatic amino acid metabolite (GDAAM) compared to a second corresponding control value, wherein the first GDAAM is selected from the following first group: phenylacetyl glycine, Phenylacetic acid, Hippuric acid, Phenylacryl glycine, p-Cresol glucuronide, 4-OH-Phenyllactic acid, 4-Ethylphenylsulfate, 4-OH- Benzoic acid, 4-OH- Hippuric acid, 2-OH-Hippuric acid, 3-OH-Hippuric acid, Indole glucuronide, 5-OH-indole-3- acetic acid, Indole-3 -acetyl glutamine, Serotonin, Indole-3 -acetic acid, Indole-3 -lactic acid, and N-Acetyl-tryptophan, and wherein the second GDAAM is selected from the following second group: Tyrosine, 2-OH-Benzoic acid, and Tryptophan; and N6-trimethyl-lysine; and b) at least one of the following: i) an agent that inhibits the TMA / FM03 / TMA0 pathway; ii) a cardiovascular disease therapeutic, and iii) an anti-thrombotic agent, iv) an anti-platelet agent, and v) an antibiotic or antimicrobial that reduces trimethylamine (TMA) production in the gut. In further embodiments, the FM03 inhibitor comprises Tenofovir or Methimazole. In particular embodiments, the antiplatelet agent is selected from the group consisting of: abciximab, dipyridamole / ASA, anagrelide, cilostazol, clopidogrel, dipyridamole, eptifabatide, prasugrel, ticagrelor, ticlopidine, tirofiban, and vorapaxar.
[0025] In some embodiments, provided herein are compositions, kits, and systems comprising: a) a sample from a subject having a cardiovascular disease, or an elevated risk of cardiovascular disease, and / or elevated risk for a thrombotic event, or with obesity or elevated risk or obesity, or elevated risk of a metabolic disorder, or having a metabolic disorder, and b) a stable isotope labeled first and / or second gut derived aromatic amino acid metabolite (GDAAM), wherein the fist GDAAM is selected from the following first group: phenylacetyl glycine, Phenylacetic acid, Hippuric acid, Phenylacryl glycine, p-Cresol glucuronide, 4-OH-Phenyllactic acid, 4-Ethylphenylsulfate, 4-OH-Benzoic acid, 4-OH- Hippuric acid, 2-OH-Hippuric acid, 3-OH-Hippuric acid, Indole glucuronide, 5-OH-indole-3- acetic acid, Indole-3 -acetyl glutamine, Serotonin, Indole-3 -acetic acid, Indole-3 -lactic acid, and N-Acetyl-tryptophan, and wherein the second GDAAM is selected from the following second group: Tyrosine, 2-OH-Benzoic acid, and Tryptophan. In certain embodiments, the stable isotope is selected from 2H, 13C, and 15N. In other embodiments, the sample comprises a plasma sample or serum sample. In further embodiments, the composition, kit, or system further comprises: c) un-labelled first and / or second GDAAM. In particular embodiments, the unlabeled first GDAAM is present in the in the sample that is increased compared to a first corresponding control value. In further embodiments, the unlabeled second GDAAM is present in the sample at a decreased level compared to a second corresponding control value. In additional embodiments, the sample further comprises a stable isotope labeled third, fourth, fifth, sixth, seventh, or eighth GDAAM selected from the first and / or second group. In further embodiments, the sample comprises at least one, or at least two, or at least three or at least four stable isotope labeled compounds: PAGln, TMAO, I3P, Hippuric acid, 4-OH-hippuric acid, 5-OH-indole-3-acetic acid, p-cresol glucuronide, pCS, IS, Tyr, Trp, Indole-3 -acetyl glutamine. In further embodiments, the compositions, kits, and systems further comprise: stable isotope labeled molecule selected from: TMAO (trimethylamine-N-oxide), trimethyllysine, Crotonobetaine, gamma butyrobetaine, carnitine, choline, and betaine.
[0026] BRIEF DESCRIPTION OF THE FIGURES
[0027] Figure 1. Association between MACE and plasma metabolites derived from phenylalanine, tyrosine and tryptophan via gut microbes. Hazard ratio (95% CI) for incident (3-year) risks for major adverse cardiac events (MACE) to gut microbial derived metabolites from aromatic amino acids in a cohort of stable cardiac patients from combined two independent cohorts (US cohort (n=4,000) and European cohort (n=833)) undergoing elective diagnostic coronary evaluation. Hazard ratio (unadjusted, filled circles) and multivariable Cox model adjusted (open circles; adjusted for age, sex, smoking, HDL, LDL, TG, hypertension, diabetes mellitus and hsCRP). Red, green and black color is for compounds positively, negatively and not associated with MACE, respectively. The 5%-95% confidence interval is indicated by line length.
[0028] Figure 2. An atlas of microbial phenylalanine and tyrosine pathways associated with MACE. Metabolic pathways for aromatic acid fermentation together with their association with MACE (red chemical structures for compounds positively associated with MACE while green structures for compounds negatively associated with MACE after adjusting for traditional risk factors and hsCRP) and effect of gut microbes depletion on their circulation levels both in humans (red arrow) and mice (blue arrow); (-) no effect. Abx= antibiotics.
[0029] Figure 3. An atlas of microbial tryptophan pathways associated with MACE. Metabolic pathways for aromatic acid fermentation together with their association with MACE (red chemical structures for compounds positively associated with MACE while green structures for compounds negatively associated with MACE after adjusting for traditional risk factors and hsCRP) and effect of gut microbes depletion on their circulation levels both in humans (red arrow) and mice (blue arrow); (-) no effect. Abx= antibiotics.
[0030] Figure 4. Association between all-cause mortality and plasma metabolites derived from phenylalanine, tyrosine and tryptophan via gut microbes. Hazard ratio (95% CI) for incident (3 -year) risks for all-cause-mortality) to gut microbial derived metabolites from aromatic amino acids in a cohort of stable cardiac patients from combined two independent cohorts (US cohort (n=4,000) and European cohort (n=833)) undergoing elective diagnostic coronary evaluation. Hazard ratio (unadjusted, filled circles) and multivariable Cox model adjusted (open circles; adjusted for age, sex, smoking, HDL, LDL, TG, hypertension, diabetes mellitus and hsCRP). Red, green and black color is for compounds positively, negatively and not associated with MACE, respectively. The 5%-95% confidence interval is indicated by line length.
[0031] Figure 5. An atlas of microbial phenylalanine and tyrosine pathways associated with 3 year all-cause mortality. Metabolic pathways for aromatic acid fermentation together with their association with all-cause mortality (death) (red chemical structures for compounds positively associated with death while green structures for compounds negatively associated with death after adjusting for traditional risk factors and hsCRP) and effect of gut microbes depletion on their circulation levels both in humans (red arrow) and mice (blue arrow); (-) no effect. Abx= antibiotics.
[0032] Figure 6. An atlas of microbial tryptophan pathways associated with 3 year all-cause mortality. Metabolic pathways for aromatic acid fermentation together with their association with all-cause mortality (death) (red chemical structures for compounds positively associated with death while green structures for compounds negatively associated with death after adjusting for traditional risk factors and hsCRP) and effect of gut microbes depletion on their circulation levels both in humans (red arrow) and mice (blue arrow); (-) no effect. Abx= antibiotics.
[0033] Figure 7. Gut microbial effect on circulating metabolites derived from phenylalanine and tyrosine in humans. Levels of metabolites derived from phenylalanine and tyrosine in healthy humans (n=10) at different time points (ntotal=51) before (Pre-Abx) oral broad spectrum antibiotics treatment to suppress the intestinal microbiota, immediately following the seven day regimen (Abx) and after a minimum three week period for antibiotic washout to permit repopulation of gut microorganisms (Post- Abx). Significance was measured by Kruskal- Wallis test (K.W.) for multiple comparisons or by Wilcoxon test for comparison of levels Pre-Abx and Abx.
[0034] Figure 8. Gut microbial effect on circulating levels of 2-Hydroxybenzoic acid, 2- hyroxyhippuric acid and 3-hydroxyhippuric acid. Levels of 2-hydroxybenzoic acid, 2- hydroxyhippuric acid and 3-hydroxyhippuric acid in healthy humans (n=10) at different time points (ntotal=51) before (Pre-Abx) oral broad spectrum antibiotics treatment to suppress the intestinal microbiota, immediately following the seven day regimen (Abx) and after a minimum three week period for antibiotic washout to permit repopulation of gut microorganisms (Post-Abx). Significance was measured by Kruskal- Wallis test (K.W.) for multiple comparisons or by Wilcoxon test for comparison of levels Pre-Abx and Abx.
[0035] Figure 9. Gut microbial effect on circulating metabolites derived from phenylalanine and tyrosine in mice. Levels of metabolites derived from phenylalanine and tyrosine in 8-10 weeks old male (n=15) and female (n=15) mice at baseline (Pre-Abx), immediately after five day exposure to oral broad spectrum antibiotics treatment to suppress the intestinal microbiota (Abx) and one week after antibiotic washout to permit repopulation of gut microorganisms (Post-Abx). P-values were calculated using Kruskal- Wallis test (K.W.) for multiple comparisons and Pre-Abx compared to Abx by Wilcoxon test.
[0036] Figure 10. Gut microbial effect on circulating metabolites derived from tryptophan in humans. Levels of metabolites derived from tryptophan in healthy humans (n=10) at different time points (ntotal=51) before (Pre-Abx) oral broad spectrum antibiotics treatment to suppress the intestinal microbiota, immediately following the seven day regimen (Abx) and after a minimum three week period for antibiotic washout to permit repopulation of gut microorganisms (Post-Abx). Significance was measured by Kruskal- Wallis test (K.W.) for multiple comparisons or Wilcoxon test for comparison of levels Pre-Abx and Abx.
[0037] Figure 11. Gut microbial effect on circulating metabolites derived from tryptophan in mice. Levels of metabolites derived from tryptophan in 8-10 weeks old male (n=15) and female (n=15) mice at baseline (Pre-Abx), immediately after five day exposure to oral broad spectrum antibiotics treatment to suppress the intestinal microbiota (Abx) and one week after antibiotic washout to permit repopulation of gut microorganisms (Post-Abx). P-values were calculated using Kruskal-Wallis test (K.W.) for multiple comparisons and Pre-Abx compared to Abx by Wilcoxon test.
[0038] Figure 12. Association between gut microbe-generated plasma metabolites derived from phenylalanine, tyrosine and tryptophan and incident MACE risk. Hazard ratio (95% CI) for incident (3-year) risks for major adverse cardiac events (MACE=MI, stroke or death) in respect to gut microbial derived metabolites from aromatic amino acids in a cohort of stable cardiac patients from two independent cohorts (US cohort (n=4,000) and European Cohort (n=833)) undergoing elective diagnostic coronary evaluation. Hazard ratio (unadjusted, filled circles) and multivariable Cox model adjusted (open circles; adjusted for age, sex, smoking, HDL, LDL, triglyceride level, hypertension, diabetes mellitus and high sensitivity C-reactive protein level). Red, green and black color is for compounds positively, negatively and not associated with MACE, respectively. The 5%-95% confidence interval is indicated by line length.
[0039] Figure 1 . Association between gut microbe-generated plasma metabolites derived from phenylalanine, tyrosine and tryptophan and incident MACE risk in fully loaded model containing cardiometabolic, sociodemographic and education. Hazard ratio (95% CI) for incident (3-year) risks for major adverse cardiac events (MACE) in respect to gut microbial derived metabolites from aromatic amino acids in a cohort of stable cardiac patients from two independent cohorts (US cohort (n=4,000) and European Cohort (n=833)) undergoing elective diagnostic coronary evaluation. Hazard ratio (unadjusted, filled circles) and multivariable Cox model adjusted (open circles; adjusted for age, sex, smoking, HDL, LDL, triglyceride level, hypertension, diabetes mellitus, high sensitivity C-reactive protein level, history of atrial fibrillation, medications for cardiometabolic diseases, alcohol consumption and education level. In the European cohort, the adjustment included all of the aforementioned variables expect education (data not available for most of the cohort). Red, green and black color is for compounds positively, negatively and not associated with MACE, respectively. The 5%-95% confidence interval is indicated by line length.
[0040] Figure 14. Associations amongst / between circulating levels of gut microbiota-derived plasma metabolite studied. Heat map showing Spearman correlation among plasma levels of indicated pairs of metabolites in individuals with preserved kidney function (eGFR>90 ml / min / 1.73 m2; US cohort (n=2,074) and European cohort (n=218)).
[0041] Figure 15 shows an exemplary patient report that provides levels of various gut derived aromatic amino acid metabolites (GDAAMs) and TMAO for lane Doe from Testing Company LLC. The patient report shows normal levels with a checkmark and in green (e.g., normal risk level), while increased risk levels are shown with a checkmark and in red (increased risk of CVD). The patient report is mailed, faxed, emailed, or sent through an internal network to Jane’s Doctor or to Jane herself or other caregiver.
[0042] Figure 16. Sequential stable subjects (n=4785) undergoing elective diagnostic cardiovascular risk assessment were consented and blood drawn. Subjects were followed longitudinally over time for incident development of major adverse cardiac events (MACE = myocardial infarction, stroke or death) over the ensuing 3 yr period. Plasma levels of metabolites shown were quantified by stable isotope dilution LC-MS / MS analysis. Shown are the relationship between increasing quartile levels of three gut microbiome generated metabolites with proven mechanistic links to cardiovascular disease pathogenesis, and incident cardiovascular disease risks. The metabolites shown are TMAO (trimethylamine N- Oxide), phenylactylglutamine (PAG), and indole- 3 -propionate (I3P or IPA). TMAO and PAG are clinically associated with incident MACE risks, and mechanistically linked to enhancing cardiovascular disease pathogenesis. In contrast, I3P is clinically and mechanistically linked to protection from cardiovascular disease, and low levels of I3P to be associated with higher MACE risks. Figure 16A shows the combination of TMAO and PAG, Figure 16B shows the combination of TMAO and I3P, and Figure 16C shows the combination of PAG and I3P. In these figures, combinations of any two of the depicted microbiome-derived metabolites are a better predictor of incident cardiovascular disease risk than each individual metabolite alone.
[0043] Figure 17 A shows Kaplan Meier survival plots (freedom from MACE) for the same Cleveland Cohort, again stratified by quartile levels of the indicated markers. Figure 17B shows a statistical comparison for the 3 year MACE rate for those with first (QI) vs 4th (Q4) quartile of TMAO, PAGln, or amongst subjects having both PAGln and TMAO in either the bottom (QI, QI) or top (Q4, Q4) quartile levels, with p value comparing the significance in group comparisons. Note that subjects with both Q4 values of TMAO and PAGln are at significantly higher 3 -year MACE risk compared to those who only have one high level (P<0.01 for comparison for each).
[0044] Figure 18 shows Kaplan Meier survival plots (freedom from MACE) for the same Cleveland Cohort, again stratified by quartile levels of the indicated markers. Figure 18A shows increasing TMAO quartile levels are associated with lower Freedom from MACE. Figure 18B shows there is a trend for lower (QI) level of I3P level and lower freedom from MACE (worse outcome). Figure 18C shows the Kaplan Meier survival plot of those with highest (Q4) TMAO level and lowest I3P (QI) are shown in blue, and are compared to those with both the lowest quartile (QI) of TMAO and highest quartile (Q4) of I3P (curve shown in red). Note that the percent Freedom from MACE in the low risk cohort (combined best values for TMAO (QI) and I3P (Q4) are lower than for QI of either marker alone. And conversely, those with worst marker levels (Q4 TMAO and QI I3P) have very poor Freedom from MACE. Thus, the combination of both markers provides added clinical prognostic value compared to either marker alone. Figure 19. In this Kaplan Meier Survival plot, those with the best overall markers amongst the three TMAO (QI), PAGln (QI) and I3P (Q4) have overall less incident MACE over 3 yrs of follow up (by year three <10% MACE rate with >90% remaining free of MACE). In contrast, the subgroup having top levels of all three markers (Q4 TMAO, Q4 PAGln, and QI I3P) experience a very high rate of MACE event (nearly 40%) over three years with only ~ 60% of subjects remaining free of MACE event during follow up. Compared to knowledge of just any one of the markers shown, knowing all three provides added clinical prognostic value (P<0.001 for each comparison individually, versus the combined prognostic value provided by all three).
[0045] Figure 20. Shown are analyses for the marker PAGln (20A) and I3P (20B) stratified by quartile. Figure 20C shows the subset of subjects having both high (Q4) PAGln and low (QI) I3P versus low (QI) PAGln and high (Q4) I3P.
[0046] Figure 21. Sequential subjects undergoing elective diagnostic cardiac evaluations (Cleveland Cohort) donated blood at baseline. Plasma metabolites were quantified by stable isotope dilution LC / MS / MS. The cohort was monitored over time with adjudicated cardiac endpoints determined. The frequency of experiencing a major adverse cardiac event (MACE=myocardial infarction, stroke or death) over the ensuing 3 year period is shown for the entire cohort stratified according to baseline plasma quartile levels of the indicated metabolites. PCS = p-cresol sulfate. TMAO = trimethylamine N-oxide. PAGln = phenylacetylglutamine. Note that the frequency of experiencing MACE increases both with increasing levels of the individual markers PCS and TMAO (21 A) and PAGln and PCS (2 IB). But even more so when extreme combinations of metabolites are present. That is, subjects with high levels of PCS and TMAO (top quartile) are at the highest rate of MACE, and those with low levels (bottom quartile) of both markers are at the lowest MACE risk in the graph at the left. And similarly, there is statistically significant additive value to having the combination of PAGln and PCS levels (i.e., those with lowest (QI) levels of both PAGln and PCS are at overall lowest 3 -year MACE event rate, while those with high level of both PAGln and PCS are at highest event rate.
[0047] Figure 22. Shown are Kaplan Meier survival plots (freedom from MACE) for the same Cleveland Cohort, again stratified by quartile levels of the indicated markers. In the graph shown at the left (Fig. 22A), increasing TMAO quartile levels are associated with lower Freedom from MACE. In the middle plot (Fig. 22B), increasing levels of PCS also show lower Freedom from MACE (worse outcome). At the right (Fig. 22C), the Kaplan Meier survival plot of those with highest (Q4) level of both TMAO and PCS are shown in red and show an even larger reduction in Freedom from MACE % (i.e., worse outcome). In comparison, those with lowest quartile (QI) levels of both TMAO and PCS (curve shown in blue) show the least reduction in Freedom from MACE (i.e., they have the best overall outcome with lowest overall MACE rate). Note that the percent Freedom from MACE in the low risk cohort (combined best values for TMAO (QI) and PCS (QI) are lower than for QI of either marker alone. And conversely, those with the combination of worst marker levels of both metabolites (Q4 TMAO and Q4 PCS) have even lower overall Freedom from MACE (compared to those with Q4 of only one of the markers; P<0.001 comparison to each). Thus, the combination of both markers provides added clinical prognostic value compared to either marker alone.
[0048] Figure 23. Shown here are similar Kaplan Meier survival plots (freedom from MACE) for the same Cleveland Cohort, this time stratified by quartile levels of PAGln (23A), PCS (23B), or the combined extreme values of both PAGln and PCS (23C). The combination of both markers provides added clinical prognostic value compared to either marker alone.
[0049] Figure 24. Sequential subjects undergoing elective diagnostic cardiac evaluations (Cleveland Cohort) are this time stratified according to baseline plasma quartile levels of the INS, indoxyl sulfate, and TMAO = trimethylamine N-oxide (24A), or PAGln = phenylacetylglutamine and INS (24B). Note that the frequency of experiencing MACE increases both with increasing levels of the individual markers INS and TMAO (left graph) and PAGln and INS (right graph). But even more so when extreme combinations of metabolites are present. That is - subjects with high levels of both INS and TMAO (top quartile) are at the highest rate of MACE, and those with low levels (bottom quartile) of both markers are at the lowest MACE risk in the graph at the left. And similarly, there is statistically significant additive value to having the combination of PAGln and INS levels (ie those with lowest (QI) levels of both PAGln and INS are at overall lowest 3-year MACE event rate, while those with high level of both PAGln and INS are at highest event rate.
[0050] Figure 25. Shown are the KM Plots of the Cleveland Cohort stratified by quartiles of each of the indicated markers alone (left and middle graphs). Versus the subgroups having the highest (Q4) levels of each marker (shown in red) versus the lowest (Q 1 ) levels of each marker. The combined presence of both markers provides additional statistical clinical prognostic value compared to just the individual marker (P<0.01 for each comparison).
[0051] Figure 26. Sequential subjects undergoing elective diagnostic cardiac evaluations (Cleveland Cohort) donated blood at baseline. Plasma metabolites were quantified by stable isotope dilution LC / MS / MS. The cohort was monitored over time with adjudicated cardiac endpoints determined. The frequency of experiencing a major adverse cardiac event (MACE=myocardial infarction, stroke or death) over the ensuing 3 year period is shown for the entire cohort stratified according to baseline plasma quartile levels of the indicated metabolites. Note that the frequency of experiencing MACE increases both with increasing level of the individual marker PCS, increasing level of INS, and lower level of I3P. Also note that subjects with extreme combinations of metabolites are at the highest or lowest cumulative rate of MACE. That is, subjects with high levels of PCS and INS (top quartile) are at the highest rate of MACE (26A), and those with low levels (bottom quartile) of both markers are at the lowest MACE risk. Similarly, additive prognostic value is seen in general with high level of PCS and low level of I3P (26B), and high level of INS and low level of I3P (26C). PCS, p-cresol sulfate; INS, indoxyl sulfate; I3P, indole-3-propionate.
[0052] Figure 27. Note that as one has results from increasing markers, and one looks at subjects with the best (in this case lowest, QI) possible level of each marker, the cumulative frequency of MACE gets less (i.e. the Freedom from MACE gets higher).
[0053] DEFINITIONS
[0054] As used herein, the terms “cardiovascular disease” (CVD) or “cardiovascular disorder” are terms used to classify numerous conditions affecting the heart, heart valves, and vasculature (e.g., veins and arteries) of the body and encompasses diseases and conditions including, but not limited to arteriosclerosis, atherosclerosis, myocardial infarction, acute coronary syndrome, angina, congestive heart failure, aortic aneurysm, aortic dissection, iliac or femoral aneurysm, pulmonary embolism, primary hypertension, atrial fibrillation, stroke, transient ischemic attack, systolic dysfunction, diastolic dysfunction, myocarditis, atrial tachycardia, ventricular fibrillation, endocarditis, arteriopathy, vasculitis, atherosclerotic plaque, vulnerable plaque, acute coronary syndrome, acute ischemic attack, sudden cardiac death, peripheral vascular disease, coronary artery disease (CAD), peripheral artery disease (PAD), and cerebrovascular disease.
[0055] As used herein, the term “atherosclerotic cardiovascular disease” or “disorder” refers to a subset of cardiovascular disease that include atherosclerosis as a component or precursor to the particular type of cardiovascular disease and includes, without limitation, CAD, PAD, cerebrovascular disease. Atherosclerosis is a chronic inflammatory response that occurs in the walls of arterial blood vessels. It involves the formation of atheromatous plaques that can lead to narrowing (“stenosis”) of the artery, and can eventually lead to partial or complete closure of the arterial opening and / or plaque ruptures. Thus atherosclerotic diseases or disorders include the consequences of atheromatous plaque formation and rupture including, without limitation, stenosis or narrowing of arteries, heart failure, aneurysm formation including aortic aneurysm, aortic dissection, and ischemic events such as myocardial infarction and stroke
[0056] The terms "individual," "host," "subject," and "patient" are used interchangeably herein, and generally refer to a mammal, including, but not limited to, primates, including simians and humans, equines (e.g., horses), canines (e.g., dogs), felines, various domesticated livestock (e.g., ungulates, such as swine, pigs, goats, sheep, and the like), as well as domesticated pets and animals maintained in zoos. In some embodiments, the subject is specifically a human subject.
[0057] As used herein “heart failure” refers to when the heart is unable to pump sufficiently to maintain blood flow to meet the body's needs. Signs and symptoms of heart failure commonly include shortness of breath, excessive tiredness, and leg swelling. The shortness of breath is usually worse with exercise, while lying down, and may wake the person at night. A limited ability to exercise is also a common feature. Common causes of heart failure include coronary artery disease including a previous or current myocardial infarction (heart attack), high blood pressure, atrial fibrillation, valvular heart disease, excess alcohol use, infection, and cardiomyopathy of an unknown cause.
[0058] DETAILED DESCRIPTION OF THE INVENTION
[0059] The present invention relates to systems, kits, and methods for identifying subjects with increased or decreased levels (e.g., in plasma) of at least one gut derived aromatic amino acid metabolite (GDAAM), as well as methods of determining the risk of cardiovascular disease, or other diseases, based on such levels. In certain embodiments, the level of at least two of the GDAAMs is employed (e.g., 2, 3, 4 or more). In some embodiments, a subject with altered levels of at least one of the GDAAMs is treated with a CVD therapeutic (e.g., lipid lowering agent) or one that inhibits the TMA / FM03 / TMA0 pathway.
[0060] Changes in both gut microbial composition and circulating levels of certain microbial metabolites have been associated with multiple human diseases, including cardiovascular disease (CVD).1’5Mechanistic studies in both humans6and animal models,7’11have further linked microbial metabolites as participants in the development or exacerbation of host CVD phenotypes. These findings have served as a basis for developing new therapeutic approaches aimed at restoring microbiome health with the use of pre- and probiotics,12’14and / or by modulating gut-microbial functional metabolic output. Illustrations of the latter approach include non-lethal inhibition (i.e. non-antibiotic) of gut microbial enzymes and sequestering or supplementing selected gut-microbial metabolites.15’18For example, the gut microbial pathway involving the conversion of choline into trimethylamine (TMA), the precursor to trimethylamine-N-oxide (TMAO), has previously been linked to the development of CVD. Animal model studies have shown that inhibiting the enzyme catalyzing choline into TMA can suppress atherosclerosis development,16reduce both thrombosis potential17, 19and renal fibrosis,20, 21improve cardiac function,22and lessen obesity.23Inhibitors of gut-bacterial bile salt hydrolases, have also been used to modulate the bile acid pool within the host,24, 25and non-lethal targeted inhibition of the gut bacterial P-glucuronidase has reportedly enhanced anticancer drag efficacy within hosts.26, 27
[0061] Precision microbiome modulation - whether by using small molecule inhibitors of specific gut microbiota-driven pathways, dietary interventions, or by changing microbial compositions and function to alter microbial community metabolic output (e.g. shifting metabolic production from potentially detrimental to potentially beneficial products for the host), requires comprehensive and quantitative analysis of microbial metabolites, as well as both an understanding of their associations with and effects on host adverse phenotypes.1, 28-32. The vast majority of metabolomics studies report only qualitative relative levels (i.e. not quantitative absolute concentrations), and are not optimized for separation of structural isomers. Consequently, results reported can be difficult to replicate, and require validation with more quantitative and robust methods specifically designed to meet the rigor of in vitro clinical diagnostics use.
[0062] Gut microbes catabolize protein aromatic amino acids tyrosine (Tyr) and tryptophan (Trp) into precursors of the well-known uremic toxins p-cresol sulfate (pCS) and indoxyl sulfate (IS), respectively.35-37pCS and IS have been associated with cardiovascular mortality in subjects with impaired renal function,38-40and have been reported to increase thrombosis potential in various in vitro and in vivo models.41-46Further, while cross sectional studies have reported the association of these uremic toxins with heightened carotid atherosclerotic plaque burden, and in individuals with relatively preserved kidney function,47, 48the relationship of classic uremic toxins like IS and pCS to incident risk of adverse cardiovascular events among subjects without renal functional impairment is unclear. Conversely, alternative microbiota associated metabolites of aromatic amino acids have been reported to be inversely associated with cardiometabolic disease risks (e.g. indole-3 -propionic acid (I3PA) and reduced diabetes risk49), or positively associated with healthy eating habits and increased microbiome diversity (e.g. hippurate50, 51).
[0063] Mapping the pathways and products of gut microbiota dependent metabolism of aromatic amino acid has not been comprehensively investigated in humans, and detailed exploration using quantitative stable isotope dilution methods of the numerous metabolites designed to provide absolute concentrations free of contaminating structural isomers has yet to be reported for most metabolites. As noted above, most studies that report metabolite associations with disease risks are cross sectional and / or qualitative (based on untargeted metabolomics), only reporting “relative levels”. The majority of such studies also do not unambiguously distinguish between structural isomers (i.e. compounds that possess the same elemental composition, physical properties, and often co-elute). Untargeted metabolomics analyses thus need to be separately validated using quantitative methods designed and verified to be both quantitative and specific for the target analytes desired.
[0064] Rational design of personalized therapeutic strategies that target gut microbiota driven pathways will require a comprehensive understanding of both gut microbial metabolism and the relationship between systemic levels of metabolites and incident CVD event risks. Thus, the aim of this work was to identify gut-microbe derived metabolites and microbial pathways associated with incident adverse CVD event risk. Gut microbial enzymes ferment essential aromatic amino acids into a plethora of small molecules via deamination, oxidation and / or reduction reactions, to name a few. As the portal vein drains blood from most of the gastrointestinal tract into the liver, some molecules derived from gut microbes are further metabolized, either fully or in part, by host liver enzymes before they reach the systemic circulation. Accordingly, we herein provide a reverse phase, stable-isotope-dilution LC- MS / MS method for the quantitative analysis of numerous metabolites potentially derived from dietary sources of the aromatic amino acids Phe, Tyr and Trp via gut bacteria. We then examined the associations between quantitative measures of these circulating metabolites in two independent cohorts of stable individuals undergoing elective diagnostic cardiac evaluation with adjudicated longitudinal follow up. In addition, we evaluate the contribution of gut microbiota to circulating metabolite levels in both human and mice intervention studies using poorly absorbed antibiotic cocktails to suppress gut microbiota. The collective data assembled, overlaid on metabolic pathways delineated, provide a map or “atlas” of microbiota-dependent metabolic pathways of aromatic amino acid catabolism associated with incident CVD risks.
[0065] In some embodiments, provided herein are methods for treatment and / or prevention of cardiovascular disease in patients identified as having elevated levels one or more first GDAAM (compared to a control) and / or decreased levels of one or more second GDAAMs using compounds and or procedures that inhibit the TMA / FM03 / TMA0 pathway. In certain embodiments, such compounds and procedures are selected from the group consisting of: : i) a compound selected from CC136 and CC272; ii) acetylsalicylic acid with or without an enteric coating; iii) an acetylsalicylic acid derivative with or without an enteric coating; iv) compound CC270; v) a gut TMA lyase inhibitor; vi) fecal microbiota transplantation and / or synthetic polymicrobial feces transplantation, and / or gut bacteria spores; vii) delivery of acetylsalicylic acid or derivative thereof directly to the colon or cecum of the subject; viii) a probiotic or prebiotic that reduces production in the gut of the first GDAAM; ix) a TMA and / or TMAO sequestering agent; x) a TMA lyase inhibitor is selected from: a halomethyl choline, iodomethylcholine, fluoromethycholine, a halomethyl betaine, a halomethyl betaine salt, a halomethyl betaine amide, and a halomethyl dimethyl amino alcohol; xi) 3-(2,2,2- trimethylhydraziniumyl) propionate; xii) a compound of any of Formulas T-TTI or V, and xiii) a compound of Formulas I-III (as described in U.S. Pat. Pub. 2018 / 0000754, which is herein incorporated by reference in its entirety, particularly for Formulas I-III).
[0066] I. Acetylsalicylic Acid Derivatives and Related Compounds
[0067] In some embodiments, the acetylsalicylic acid derivative or related compound is selected from the group consisting of: 4-Methylsalicylic acid, 5-(acetylamino)-2- hydroxybenzoic acid; Salicylic acid, sodium salt, 4-Aminosalicylic acid, 3-Methylsalicylic acid, 3 -Nitrosalicylic acid, 1 -Hydroxy-2-naphthoic acid, 2-Hydroxyethyl salicylate, 5- Bromosalicylic acid, 5 -Methylsalicylic acid, 5-Aminosalicylic acid, 2,4-Dihydroxybenzoic acid, 2,4-Dimethoxybenzoic acid, 3-Hydroxy-2-naphthoic acid, 5-Nitrosalicylic acid, Phenyl salicylate, Ethyl salicylate, 5-Iodosalicylic acid, Methyl salicylate, 5, 5 '-Methylenedisalicylic acid, Pamoic acid, 2-Ethoxybenzoic acid, 2,6-Dihydroxybenzoic acid, 2,3-Dihydroxybenzoic acid, Ochratoxin A, 5-Chlorosalicylic acid, 4-Fluorosalicylic acid, Methyl 5-fluoro-2- hydroxybenzoate, 2,4,5-Trimethoxybenzoic acid, 2,5-Dihydroxybenzoic acid, Acetylsalicylsalicylic acid, Salicylsalicylic acid, 6-Methylsalicylic acid, Aluminon, 3- Aminosalicylic acid, 2,3,4-Trimethoxybenzoic acid, o- Anisic acid, Isopropyl salicylate, 3,5- Dinitrosalicylic acid, 2,3,4-Trihydroxybenzoic acid, 5-Formylsalicylic acid, 2-Hydroxy-4- nitrobenzoic acid, Lithium 3,5-diiodosalicylate, 4-Fluorosulfonyl- 1 -hydroxy-2-naphthoic acid, 3 -Methoxy salicylic acid, Methyl l-hydroxy-2-naphthoate, Carminic acid, Carmine (pure, alum lake of carminic acid), Carmine (high purity biol.stain, alum lake of carminic acid), 2,6-Dimethoxybenzoic acid, 2,3-Dimethoxybenzoic acid, Chrome Azurol S, Alizarin Yellow R sodium salt, 3 -Chlorosalicylic acid, 2- (trifluoromethoxy )benzoic acid, Methyl 2,4- dimethoxybenzoate, Methyl 2,6-dihydroxybenzoate, Methyl 2,4-dihydroxybenzoate, Triethanolamine salicylate, 2-Ethoxynaphthoic acid, 4-Methoxy salicylic acid, 5- Methoxysalicylic acid, 2,5-Dimethoxybenzoic acid, 3,5 Dibromosalicylic acid, 6- Methoxy salicylic acid, 5-Chloro-o-anisic acid, Chromoxane Cyanine R, 3-Hydroxy-4-(2- hydroxy-4-sulfo-l-naphthylazo)naphthalene-2-carboxylic acid, indicator grade ethyl 2,3-dihydroxybenzoate, Methyl 5-iodosalicylate, methyl 5-chloro-2-hydroxybenzoate, Methyl 4-acetamido-5-chloro-2-methoxybenzoate, 2-(acetyloxy)-3-methylbenzoic acid, 2- (acetyloxy)-3 -methylbenzoic acid, l,4-Benzodioxan-5-carboxylic acid, 2-Methoxy-5- (trifluoromethyl)benzoic acid, 4-Chlorosalicylic acid, Methyl 4-methoxysalicylate, 1,3- benzodioxole-4-carboxylic acid, 5-Sulfosalicylic acid dihydrate, 5 -Sulfosalicylic acid dihydrate, 5 -Sulfosalicylic acid dihydrate, Mordant Yellow 10, 4-Amino-5-chloro-2- methoxybenzoic acid, Methyl 5 -acetylsalicylate, 5-chlorosulfonyl-2-hydroxybenzoic acid, methyl 2-[2-(dimethylamino)ethoxy]benzoate, alpha-Apo-oxytetracycline, beta-Apo- oxytetracycline, 3,5-Di-tert-butylsalicylic acid, Methyl 3,5-dibromo-2-hydroxybenzoate, 2- (3-methoxyphenoxy)benzoic acid, Methyl 3 -nitrosalicylate, Methyl 5 -methylsalicylate, methyl 4-amino-2-methoxybenzoate, chroman-8-carboxylic acid, methyl 2,5-di(2,2,2- trifluoroethoxy)benzoate, 2,3 dihydrobenzo[b]furan-7-carboxylic acid, methyl 3-amino-2- hydroxybenzoate, 3-chloro-2,6-dimethoxybenzoic acid, 3-Hydroxyphthalic anhydride, 5- Bromo-2,3-dihydrobenzo[b]furan-7-carboxylic Acid, 2,2-dimethyl-2,3-dihydro-l- benzofuran-7-carboxylic acid, 6-Fluorosalicylic acid, 2,4,6-Trihydroxybenzoic acid monohydrate, 3-bromo-2,6-dimethoxybenzoic acid, 3-bromo-2,6-dimethoxybenzoic acid, 3,5-dichloro-2,6-dimethoxybenzoic acid, Lavendustin A, 2-Fluoro-6-methoxybenzoic acid, 5- Bromo-2,4-dihydroxybenzoic acid monohydrate, 3-chloro-2,6-dimethoxy-5-nitrobenzoic acid, methyl 4,7-dibromo-3-methoxy-2-naphthoate, 2-(trifluoromethoxy)terephthalic acid, 2- methoxy-4,6-di(trifluoromethyl)benzoic acid, 2-[2-(dimethylamino)ethoxy]benzoic acid, 2- [(5-chloro-3-pyridyl)oxy]-5-nitrobenzoic acid, 6-fluoro-4H-l ,3 -benzodioxine- 8-carboxylic acid, 3-Methoxy-4-(methoxycarbonyl)phenylboronic acid pinacol ester, 3-Methoxy-4- (methoxycarbonyl)phenylboronic acid, 2-(tetrahydropyran-4-yloxy)benzoic acid, pentafluorophenyl 2-(tetrahydro-2H-pyran-4-yloxy)benzoate, 3-Hydroxy-4- (methoxycarbonyl)phenylboronic acid pinacol ester, and 3-Formylsalicylic acid hydrate.
[0068] IL Antibiotics
[0069] In certain embodiments, the antibiotic used to treat the subject include, but are not limited to, Ampicillin; Bacampicillin; Carbenicillin Indanyl; Mezlocillin; Piperacillin; Ticarcillin; Amoxicillin-Clavulanic Acid; Ampicillin-Sulbactam; Benzylpenicillin; Cioxacillin; Dicloxacillin; Methicillin; Oxacillin; Penicillin G; Penicillin V; Piperacillin Tazobactam; Ticarcillin Clavulanic Acid; Nafcillin; Cephalosporin I Generation; Cefadroxil; Cefazolin; Cephalexin; Cephalothin; Cephapirin; Cephradine; Cefaclor; Cefamandol; Cefonicid; Cefotetan; Cefoxitin; Cefprozil; Ceftmetazole; Cefuroxime; Loracarbef; Cefdinir; Ceftibuten; Cefoperazone; Cefixime; Cefotaxime; Cefpodoxime proxetil; Ceftazidime; Ceftizoxime; Ceftriaxone; Cefepime; Azithromycin; Clarithromycin; Clindamycin;
[0070] Dirithromycin; Erythromycin; Lincomycin; Troleandomycin; Cinoxacin; Ciprofloxacin;
[0071] Enoxacin; Gatifloxacin; Grepafloxacin; Levofloxacin; Lomefloxacin; Moxifloxacin;
[0072] Nalidixic acid; Norfloxacin; Ofloxacin; Sparfloxacin; Trovafloxacin; Oxolinic acid;
[0073] Gemifloxacin; Perfloxacin; Imipenem-Cilastatin Meropenem; Aztreonam; Amikacin;
[0074] Gentamicin; Kanamycin; Neomycin; Netilmicin; Streptomycin; Tobramycin; Paromomycin;
[0075] Teicoplanin; Vancomycin; Demeclocycline; Doxycycline; Methacycline; Minocycline;
[0076] Oxytetracycline; Tetracycline; Chlortetracycline; Mafenide; Silver Sulfadiazine;
[0077] Sulfacetamide; Sulfadiazine; Sulfamethoxazole; Sulfasalazine; Sulfisoxazole; Trimethoprim-
[0078] Sulfamethoxazole; Sulfamethizole; Rifabutin; Rifampin; Rifapentine; Linezolid;
[0079] Streptogramins; Quinopristin Dalfopristin; Bacitracin; Chloramphenicol; Fosfomycin;
[0080] Isoniazid; Methenamine; Metronidazol; Mupirocin; Nitrofurantoin; Nitrofurazone;
[0081] Novobiocin; Polymyxin; Spectinomycin; Trimethoprim; Colistin; Cycloserine; Capreomycin;
[0082] Ethionamide; Pyrazinamide; Para-aminosalicyclic acid; and Erythromycin ethylsuccinate.
[0083] III. Halomethyl and Morpholine Compounds
[0084] In certain embodiments, the halomethyl and morpholines compounds used to treat the subject are as shown in Table 1 below.
[0085] TABLE 1 III. Compounds of Formulas I-III and Formula V
[0086] In certain embodiments, the compound used in the methods and systems herein is as shown in any of Formulas I-III as shown below, and as provided in U.S. Pat. Pub. 2018 / 0000754, which is herein incorporated by reference in its entirety, particularly for
[0087] Formulas I-III. In some embodiments, the compound used to treat a subject (e.g., with elevated or decreased GDAAMs are as shown in Formula V as shown below, and as provided in U.S. Pat. Pub. 20170152222, which is herein incorporated by reference in its entirety. Formula I is as follows: wherein R1 is selected from: wherein Z is selected from: C, CH, CH2, or O; wherein R2 and R3 are independently selected from C 1-C4 alkyl, allyl, propargyl, or
[0088] CH2 when part of an aliphatic, carbocyclic, or heterocyclic ring system; wherein R4 is selected from: H, C1-C4 alkyl, allyl, alkyl carboxyl, alkyl carboxylate, alkyl ester, hydroxy alkyl, alkoxy alkyl, propargyl, amine, or amino alkyl; wherein R5 is selected from: H, or C1-C4 alkyl; wherein R6 is independently selected from hydroxyl, C1-C4 alkoxy, or oxygen when part of a ring system, and; wherein R7 is selected from: H, C1-C4 alkyl, or is absent when the carboxylate ion exists as part of a betaine, inner salt, or Zwitterion form; wherein Y+ is a quaternary nitrogen; wherein X- is a pharmaceutically acceptable anion; and wherein n is 1 , 2, 3 or 4, and including any acceptable salts or solvates thereof.
[0089] Formula II is as follows: wherein R9 and RIO are independently selected from: C1-C4 alkyl, wherein Rl l is propargyl, wherein Y+ is a quaternary nitrogen, wherein X- is a pharmaceutically acceptable anion, and wherein n is 1 , 2, 3 or 4, and including any acceptable salts or solvates thereof.
[0090] Formula III is as follows:
[0091] R12 is selected from:
[0092] wherein W is CH2, or 0; wherein R13 and R14 are independently selected from: C1-C4 alkyl, or propargyl; wherein R15 is selected from: C1-C4 alkyl, hydroxy ethyl, or propargyl; wherein R5 is selected from: H, or C1-C4 alkyl; wherein R6 is independently selected from: hydroxyl, C1-C4 alkoxy, or oxygen when part of a ring system; wherein R16 is selected from: H, C1-C4 alkyl, or a negative charge when [O] exists as a carboxylate anion; wherein Y+ is a quaternary nitrogen; wherein X- is a pharmaceutically acceptable anion; and wherein n is 1 , 2, 3 or 4, and including any acceptable salts or solvates thereof.
[0093] In some embodiments, compounds of Formulas I-III are shown in Table 2. In table 2, compounds marked by * fall under Formula (I); compounds marked by A fall under Formula (II), and compounds marked by # fall under Formula (III). Salt forms may include, but are not limited to, chloride, bromide, or iodide.
[0094] TABLE 2
[0095]
[0096]
[0097] In certain embodiments in the above table, for example, the compounds 40,41,42 also include analogues that has the fluoromethyl group as a halomethyl (i.e., the propargyl on one side (CHC=CH2-) and fluoromethyl (CH2F) on the other). In some embodiments, the compound used to treat a subject with increased or decreased GDAAMs (compared to a control) is as shown in Formula V below, and as provided in U.S. Pat. Pub. 20170152222, which is herein incorporated by reference in its entirety. Formula (V): wherein
[0098] Y+ is selected from a quaternary nitrogen;
[0099] X- is any pharmaceutically acceptable salt; n is selected from 1, 2 or 3;
[0100] R2 and R3 are independently selected from C 1 -4 alkyl or bound together forming an aliphatic, aromatic or heterocyclic ring system;
[0101] R4 is selected from Cl -4 alkyl, alkenyl, alkynyl, alkoxy carbonyl, alkoxy dicarbonyl, acrylic, alkoxy, alkoxy alkyl, aryloxy alkyl, alkyl carboxylate as part of a betaine, inner salt, or Zwitterion form, halo alkyl, hydroxy alkyl, nitrile, or propargyl; and
[0102] R6 is selected from Cl-4 alkyl, alkoxy, hydroxy, alkoxy alkyl, hydroxy alkyl, or epoxy; and including any acceptable salts or solvates thereof.
[0103] In certain embodiments, the used to treat a subject with increased or decreased GDAAMs (compared to a control) is as shown in Table 11 below, or any of the compounds disclosed in US Pat. 10,675,256 or W02020118238, both of which are incorporated herein by reference, particularly for the compounds disclosed therein.
[0104] TABLE 11
[0105]
[0106] IV. Control Values
[0107] In certain embodiments, levels of the first and / or second GDAAMs in the sample
[0108] (e.g., biological sample) obtained from the subject may compared to a control value (e.g., to know if the GDAAM is the same, increased, or decreased compared to the control). A control value is a concentration of an analyte that represents a known or representative amount of an analyte. For example, the control value can be based upon levels of the selected GDAAM in comparable samples obtained from a reference cohort. In certain embodiments, the reference cohort is the general population. In certain embodiments, the reference cohort is a select population of human subjects. In certain embodiments, the reference cohort is comprised of individuals who have not previously had any signs or symptoms indicating the presence of cardiovascular disease or atherosclerosis, such as angina pectoris, or history of an acute adverse cardiovascular event such as a myocardial infarction or stroke, or evidence of atherosclerosis by diagnostic imaging methods including, but not limited to coronary angiography. In certain embodiments, the reference cohort includes individuals, who if examined by a medical professional would be characterized as free of symptoms of disease (e.g., cardiovascular disease). In another example, the reference cohort may be individuals who are nonsmokers (i.e., individuals who do not smoke cigarettes or related items such as cigars). A nonsmoker cohort may have a different normal range of the selected GDAAM than will a smoking population or the general population. Accordingly, the control values selected may take into account the category into which the test subject falls. Appropriate categories can be selected with no more than routine experimentation by those of ordinary skill in the art.
[0109] The control value is preferably measured using the same units used to characterize the level of the selected GDAAM obtained from the subject. Thus, if the level of the selected GDAAM is an absolute value such as the units of the GDAAM per ml of blood or plasma, the control value is also based upon the units of the GDAAM per ml of blood or plasma in individuals in the general population or a select population of human subjects.
[0110] The control value can take a variety of forms. The control value can be a single cutoff value, such as a median or mean. The control value can be established based upon comparative groups such as where the risk in one defined group is double the risk in another defined group. The control values can be divided equally (or unequally) into groups, such as a low risk group, a medium risk group and a high-risk group, or into quadrants, the lowest quadrant being individuals with the lowest risk the highest quadrant being individuals with the highest risk, and the test subject's risk of having CVD can be based upon which group his or her test value falls. Control values of the selected GDAAM in biological samples obtained, such as mean levels, median levels, or "cut-off levels, are established by assaying a large sample of individuals in the general population or the select population and using a statistical model such as the predictive value method for selecting a positivity criterion or receiver operator characteristic curve that defines optimum specificity (highest true negative rate) and sensitivity (highest true positive rate) as described, for example, in Knapp, R. G., and Miller, M. C. (1992). Clinical Epidemiology and Biostatistics. William and Wilkins, Harual Publishing Co. Malvern, Pa., which is specifically incorporated herein by reference. A "cutoff value can be determined for each GDAAM that is assayed.
[0111] Comparison of a selected GDAAM obtained from a Subject to a Control Value
[0112] Levels of a selected first or second GDAAM in a subject's biological sample may be compared to a single control value or to a range of control values. In certain embodiments, a first GDAAM is selected from the following first group: phenylacetyl glycine, Phenylacetic acid, Hippuric acid, Phenylacryl glycine, p-Cresol glucuronide, 4-OH-Phenyllactic acid, 4- Ethylphenylsulfate, 4-OH-Benzoic acid, 4-OH-Hippuric acid, 2-OH-Hippuric acid, 3-OH- Hippuric acid, Indole glucuronide, 5-OH-indole-3-acetic acid, Indole-3 -acetyl glutamine, Serotonin, Indole-3 -acetic acid, Indole-3-lactic acid, and N-Acetyl-tryptophan, and optionally phenylacetyl glutamine, and a second GDAAM is selected from the following second group: Tyrosine, 2-OH-Benzoic acid, and Tryptophan. If the level of a first GDAAM risk predictor in the test subject's biological sample is greater than the control value (or if the level of a second GDAAM is below the control value) or exceeds or is in the upper range of control values, the test subject is at greater risk of developing or having CVD or experiencing an adverse cardiac event within the ensuing year, two years, and / or three years than individuals with levels comparable to or below the control value (or above the control value for the second GDAAM markers) or in the lower range of control values. In contrast, if levels of the first GDAAM marker in the test subject’s biological sample is below the control value (or higher than the control value for the second GDAAM markers) or is in the lower range of control values, the test subject is at a lower risk of developing or having CVD or experiencing an adverse cardiac event within the ensuing year, two years, and / or three years than individuals whose levels are comparable to or above the control value or exceeding or in the upper range of control values. The extent of the difference between the test subject’s first or second GDAAM levels and control value is also useful for characterizing the extent of the risk and thereby determining which individuals would most greatly benefit from certain aggressive therapies. In those cases, where the control value ranges are divided into a plurality of groups, such as the control value ranges for individuals at high risk, average risk, and low risk, the comparison involves determining into which group the test subject's level of the relevant risk predictor falls.
[0113] Another type of control value is an internal standard in the sample. An internal standard is a known amount of another compound that can be provided in a sample that can be measured along with the analyte to serve as a reference. The diagnostic methods described herein can also be carried out by determining the levels of a selected GDAAM in a subject's biological sample and comparing them to the amount of an internal standard.
[0114] EXAMPLES
[0115] The following examples are for purposes of illustration only and are not intended to limit the scope of the claims.
[0116] EXAMPLE 1
[0117] An atlas of gut microbe-derived products from aromatic amino acids associated with incident risk of major adverse cardiovascular events and mortality
[0118] Precision microbiome modulation as a novel treatment strategy is a rapidly evolving and sought goal. The aim of this Example is to determine relationships among systemic gut microbial metabolite levels and incident cardiovascular disease risks to identify gut microbial pathways as possible pharmacological targets for personalized therapeutic interventions.
[0119] Stable isotope dilution mass spectrometry methods to quantitatively measure aromatic amino acids and their metabolites were used to examine sequential subjects undergoing elective diagnostic cardiac evaluation in two independent cohorts with longitudinal outcome data (US ( n=4,000) and EU (n=833) cohorts). It was also used in plasma from humans and mice before versus after a cocktail of poorly absorbed antibiotics to suppress gut microbiota. The results indicate that multiple aromatic amino acid-derived metabolites that originate, at least in part, from gut bacteria are associated with incident (3 year) major adverse cardiovascular event risks (MACE= myocardial infarction, stroke or death) and all-cause mortality independent of traditional risk factors. Key gut microbiota-derived metabolites associated with incident MACE and poorer survival risks include: (i) phenylacetyl glutamine and phenylacetyl glycine (from phenylalanine); (ii) p-cresol (from tyrosine) yielding p-cresol sulfate and p-cresol glucuronide; (iii) 4-OH-phenyllactic acid (from tyrosine) yielding 4-OH- benzoic acid and 4-OH-hippuric acid; (iv) indole (from tryptophan) yielding indole glucuronide and indoxyl sulfate; (v) indole-3-pyruvic acid (from tryptophan) yielding indole- 3-lactic acid and indole-3-acetyl-glutamine, and (vi) 5-OH-indole-3-acetic acid (from tryptophan). In conclusion, there are key gut microbiota-generated metabolites derived from aromatic amino acids independently associated with incident adverse cardiovascular outcomes.
[0120] METHODS
[0121] Study approvals
[0122] All clinical study protocols and informed consent for human subjects complied with the Declaration of Helsinki, and received ethical approval by the Cleveland Clinic Institutional Review Board or the ethics committee of Charite-Universitatsmedizin Berlin. Written informed consent was obtained from all subjects. All animal model studies were approved by the Institutional Animal Care and Use Committee at the Cleveland Clinic.
[0123] Human Subjects
[0124] US Cohort - GeneBank
[0125] All subjects gave written informed consent, and study protocols were approved by the Cleveland Clinic Institutional Review Board. The cohort (n=4,000) was obtained from sequential consenting subjects enrolled in the study GeneBank (Clinical Trials Identifier NCT00590200), a well-characterized cohort with broad geographic catchment from the tertiary referral center, the Cleveland Clinic. GeneBank subjects were comprised of sequential stable subjects 18 years of age or older without evidence of acute coronary syndrome (ACS) (cardiac troponin I <0.03 ng / ml) undergoing elective diagnostic coronary angiography (cardiac catheterization or coronary computed tomography) for evaluation of CVD risk.3, 10 All patients were followed prospectively over the ensuing 3 years by telephone contact, mailing, and medical record review by designated research personnel independent of study investigators. All major adverse cardiovascular events (MACE), defined as death, nonfatal MI, or nonfatal stroke after enrollment, were adjudicated with source documentation. Significantly obstructive coronary artery disease (CAD) was defined as any clinical history of MI, percutaneous coronary intervention, coronary artery bypass graft surgery, or angiographic evidence of CAD (>50% stenosis) in >1 major coronary artery. Subsequent MI was adjudicated from source documentation with supporting evidence including elevated cardiac enzymes, significant Q-wave definitive electrocardiographic evidence of new infarction, the presence of myocardial wall akinesis or scar on imaging, or treatment with thrombolytic agents or direct percutaneous intervention. Stroke was defined as documented loss of neurologic function caused by an ischemic event with residual symptoms continuing >24 hours after onset (not to include transient ischemic attacks, microvascular infarcts, or amarosis fugax). High-sensitivity C-reactive protein, lipid profiles, fasting glucose, creatinine, troponin, and hemoglobin A1C were all measured on a Roche Cobas platform (Roche Diagnostics, Basel, Switzerland). Estimated glomerular filtration rate (eGFR) was calculated on the basis of the Chronic Kidney Disease Epidemiology Collaboration 2021 CKD-EPI Creatinine equation.52
[0126] EU Cohort - LipidCardio
[0127] Plasma samples (n=833) were also obtained from subjects enrolled in the LipidCardio study at the Charite-Universitatsmedizin, Berlin, which aims to study the role of lipoproteins in cardiovascular disease.53The study was approved by the local research ethics committee (approval number: EA1 / 135 / 16) and registered under German Clinical Trial Register (drks.de); Identifier: DRKS00020915. All participants provided written informed consent. Patients aged 18 years and older undergoing elective diagnostic cardiac catheterization at a single large academic center (Department of Cardiology, Campus Benjamin Franklin, Charite-Universitatsmedizin Berlin), except those with ACS, were eligible for inclusion. All patients were followed prospectively over the 3 years. In this cohort acute ischemic stroke was diagnosed by a neurologist (according to current guidelines) and confirmed by cerebral imaging (CT or MRI). MI was defined as the detection of a rise and / or fall of troponin with at least one value above the 99th percentile URL and with at least one of the following: symptoms of acute myocardial injury, new ischemic electrocardiography changes, development of pathological Q waves, imaging evidence of new loss of viable myocardium or new regional wall motion abnormality in a pattern consistent with an ischemic etiology, and identification of a coronary thrombus by angiography.
[0128] The description of both cohort studies in this Example is in compliance with the STrenghtening the Reporting of Observational studies in Epidemiology (STROBE).54 Suppression of gut microbiota in subjects using oral antibiotics
[0129] In additional studies, healthy volunteers (n=10) were subjected to a cocktail of oral poorly absorbed antibiotics for 7 days (ciprofloxacin, metronidazole and vancomycin; or ciprofloxacin, metronidazole, vancomycin and neomycin), as previously described.3Volunteers were not pregnant and did not have a chronic illness (including known history of heart failure, renal failure, pulmonary disease, gastrointestinal disorders, or hematologic diseases). Blood was collected after overnight fasting and then, following consumption of breakfast and eating ad libitum, serially at 2, 4, 6, 8, and 24 h later on 3 different days (relative to antibiotic use) as follows: at baseline (before antibiotics treatment; pre-Abx), immediately following the 7 day antibiotics regimen (Abx), and after an antibiotics washout period (minimum three weeks) to permit repopulation of normal gut microorganisms (Post- Abx). Antibiotic suppression of gut microbial metabolite levels in humans were performed from samples collected in the pilot phase under an approved protocol registered under Clinical Trials Identifier: NCT01731236 (version Submitted Date: November 16, 2012).
[0130] Animal studies
[0131] All animal studies adhered to protocols approved by the Cleveland Clinic Institutional Animal Care and Use Committee. The impact of gut microbes on metabolite levels was studied in mice.
[0132] Targeted LC-MS / MS Analysis of Human and Mouse Plasma Samples
[0133] Stable-isotope-dilution LC-MS / MS was used for quantification of metabolites in plasma using methods optimized for each of the indicated metabolites (including use of synthetic (as needed) or commercial isotope labeled internal standards). Details of sample preparation, internal standards used, and LC-MS / MS conditions are provided below.
[0134] Targeted LC-MS / MS Analysis of Human and Mouse Plasma Samples
[0135] Stable-isotope-dilution LC-MS / MS was used for quantification of metabolites in (20 pL) plasma. Ice cold methanolic solution of internal standards (D4-serotonin; Ds-indole-3- acetic acid; D2-indole-3 -propionic acid; D5-methyl-indole-3-acetic acid; Ds- phenylacetylglutaimine; D2-5-OH-indole-3-acetic acid; Ds-hippuric acid;13C215N2-2-OH- hippuric acid; De-indole; D2-phenylpropionylglycine; Ds-tryptophan; Ds-benzoic acid;13C2- phenylacetic acid; Dy-phneylpropionic acid; Dv-phenylacrylic acid; D4-2-OH-benzoic acid; D4-4-OH-benzoic acid; D?-p-cresol sulfate; D4-indoxyl sulfate; D?-p-cresol glucuronide) was added to plasma samples (80 pL), followed by vortexing and centrifuging (21,000 x g; 4 °C for 15 min). The clear supernatant was then transferred to glass vials with microinserts. LC-MS / MS analysis was performed on a chromatographic system consisting of two Shimadzu LC-30 AD pumps (Nexera X2), a CTO 20AC oven operating at 30 °C, and a SIL- 30 AC -MP autosampler in tandem with 8050 triple quadruple mass spectrometer (Shimadzu
[0136] Scientific Instruments, Inc., Columbia, MD, USA). A Kinetex C18 column (50 mm x 2. 1 mm; 2.6 pm) (Cat # 00B-4462-AN, Phenomenex, Torrance, CA) was used for chromatographic separation. Solvent A (0.1 % acetic acid in water) and B (0.1 % acetic acid in acetonitrile) were run using the following gradient: 0.0 min (0% B); 0.0-2.0 min (0% B); 2.0- 5.0 min (0%B^20%B); 5.0-6.0 min (20%B^60%B); 6.0-7.5 min (60%B^70%B); 7.5-8.0 min (70%B^ 100%B); 8.0-9.5 min (100%); 9.5-10 min (100%B^0%B); 10.0-15.0 min (0% B) with a flow rate of 0.4 mL / min and a 1 pL injection volume. Electrospray ionization in positive and negative ion mode with multiple reaction monitoring (MRM) conditions are shown in Table 3.
[0137] Table 3. Mass spectrometry conditions for selected metabolites
[0138] ParentFra9me Fra9meQ R. Ch
[0139] Metabolite name , , , nt T nt 2#.... CE (eV) Rod Internal Standard
[0140] ESI(m / z)(m / z) (m / z)(V)(V)
[0141] Serotonin + 177.2 115.2 160.1 -12 -28 -21 D4-Serotonin
[0142] Tryptamine + 161.0 144.1 117.1 -18 -14 -15 D4-Tryptamine lndole-3-acetic acid + 176.0 130.1 103.2 -19 -18 -23 Ds-lndole-3-acetic acid lndole-3-propionic acid + 190.0 130.1 103.1 -21 -19 -25 D2-lndole-3-propionic acid
[0143] Methyl-indole-3-acetic + 190.0 130.1 103.1 -21 -19 -25 Ds-Methyl-indole-3-acetic acid acid lndole-3-pyruvic acid + 203.8 158.2 130.2 -22 -13 -17 D2-lndole-3-propionic acid lndole-3-acrylic acid + 188.0 115.1 170.1 -13 -28 -28 D2-lndole-3-propionic acid lndole-3-lactic acid + 206.2 118.1 130.2 -14 -21 -23 D2-lndole-3-propionic acid
[0144] Phenylacetylglutamine + 265.2 130.2 91.2 -19 16 -25 Ds- Phenylacetylglutamine
[0145] (PAGIn)
[0146] Phenylacetylglycine + 198.8 76.1 91.1 -21 -10 -30 Ds- Phenylacetylglutamine
[0147] (PAGIy) lndole-3-acetyl glycine + 233.2 130.2 77.3 -17 -22 -13 Ds- Phenylacetylglutamine lndole-3-acetyl + 304.0 130.2 147.1 -14 -26 -28 Ds- Phenylacetylglutamine glutamine
[0148] A / -Acetyl-tryptophan + 247.2 159.2 201.2 -17 -19 -30 Ds-Tryptophan
[0149] Hippuric acid + 180.0 105.1 77.1 -20 -13 -20 Ds-Hippuric acid 2-OH-Hippuric acid 195.8 121.1 93.2 -22 -15 -2313C215Ni -2-OH-Hippuric acid
[0150] 3-OH-Hippuric acid + 195.8 121.1 93.2 -22 -15 -23I 3C2I 5NI -2-OH-Hippuric acid
[0151] 4-OH-Hippuric acid + 195.8 121.1 93.2 -22 -15 -2313C215Ni -2-OH-Hippuric acid
[0152] Indole 1 18.0 91.2 NA -13 -23 -17 De-lndole
[0153] Phenylpropionylglycine + 207.8 105.3 76.2 -27 -19 -19 D2- Phenylpropionylglycine
[0154] Phenylacrylglycine + 205.8 103.2 NA -22 -28 -20 D2- Phenylpropionylglycine
[0155] 4-OH- + 210.2 107.2 76.2 -15 -22 -20 Ds- Phenylacetylglutamine
[0156] Phenylacetylglycine
[0157] 5-OH-lndole-3-acetic + 192.0 146.1 NA D2-5-OH-lndole-3-acetic acid acid
[0158] Benzoic acid 23 15 28 Ds-Benzoic acid
[0159] Phenylacetic acid - 135.0 91.0 NA 10 10 1013C2-Phenylacetic acid
[0160] Phenylpropionic acid - 149.5 105.1 89.1 15 14 17 Dg-Phenylpropionic acid
[0161] Phenylpyruvic aci - 163.1 91.0 119.0 16 1 1 28 Dy-Phenylacerylic acid
[0162] Phenylacrylic acid - 147.0 103.1 77.1 1 1 13 17 Dy-Phenylacerylic acid
[0163] Phenyllactic acid - 165.5 103.1 146.9 16 17 10 Dy-Phenylacerylic acid
[0164] 2-OH-Benzoic acid - 136.9 93.1 NA 10 14 16 D4-2-OH-Benozic acid
[0165] 3-OH-Benzoic acid 136.9 93.1 NA 10 14 16 D4-4-OH-Benozic acid
[0166] 4-OH-Benzoic acid 136.9 93.1 NA 10 14 16 D4-4-OH-Benozic acid
[0167] 4-OH-Phenylacetic acid 151.5 107.1 79.2 1 1 D4-2-OH-Benozic acid
[0168] 4-OH-Phenylpropionic 165.5 59.1 121.2 12 1 1 22 D4-2-OH-Benozic acid acid
[0169] 3-OH-Phenylpropionic 165.5 121.1 106.5 12 13 12 D4-2-OH-Benozic acid acid
[0170] 4-OH-Phenyllactic acid 181.1 163.2 134.9 20 D4-2-OH-Benozic acid
[0171] 4-OH-Phenylpyruvic 179.1 107.1 NA 13 10 20 D4-2-OH-Benozic acid acid
[0172] 4-OH-Phenylacrylic D4-2-OH-Benozic acid acid p-Cresol sulfate 186.7 107.0 79.9 1 1 23 15 Dy-p-Cresol sulfate
[0173] Indoxyl sulfate 211.9 79.05 132.0 13 23 28 Ds-lndoxyl sulfate p-Cresol glucuronide 282.9 107.1 113.1 20 Dy-p-Cresol glucuronide
[0174] Indoxyl glucuronide 307.9 132.0 113.2 21 22 23 Dy-p-Cresol glucuronide
[0175] 4-Ethyphenyl sulfate 201.2 121.1 106.1 14 21 22 Dy-p-Cresol sulfate Internal Standards
[0176] D4-Serotonin + 181.2 118.1 164.1 -12 -30 -21 NA
[0177] D4-Tryptamine + 164.9 148.2 118.2 -21 -14 -15 NA
[0178] Ds-lndole-3-acetic acid + 181.2 134.3 NA -13 -17 -26 NA
[0179] D2-lndole-3-propionic + 191.8 130.1 103.1 -21 -17 -26 NA acid
[0180] Ds-Methyl-indole-3- + 195.1 134.1 135.1 -12 -16 -25 NA acetic acid
[0181] Ds- + 270.1 130.1 96.2 -19 -15 -25 NA
[0182] Phenylacetylglutamine
[0183] Ds-Tryptophan + 210.0 150.1 NA -24 -17 -30 NA
[0184] D2-5-OH-lndole-3- + 194.2 148.1 NA -14 -17 -15 NA acetic acid
[0185] Ds-Hippuric acid + 185.0 110.2 82.2 -20 -14 -11 NA
[0186] 13C215NI -2-OH- + 198.8 121.1 62.3 -23 -15 -23 NA
[0187] Hippuric acid
[0188] De-lndole + 124.2 96.1 NA -20 -23 -21 NA
[0189] D2- + 208.7 105.2 77.2 -12 -22 -21 NA
[0190] Phenylpropionylglycine
[0191] Ds-Benzoic acid - 126.5 82.2 NA 28 14 30 NA
[0192] 13C2-Phenylacetic acid - 137.0 92.0 93.0 25 10 16 NA
[0193] Dg-Phenylpropionic - 158.2 114.1 NA 12 14 21 NA acid
[0194] DyPhenylacrylic acid - 154.9 110.1 NA 22 13 17 NA
[0195] D4-2-OH-Benozic acid - 141.5 97.1 69.1 10 17 17 NA
[0196] D4-4-OH-Benozic acid - 141.5 97.1 69.1 15 16 16 NA
[0197] Dyp-cresol sulfate - 193.9 114.1 80.1 13 22 21 NA
[0198] D4- Indoxyl sulfate - 215.5 79.9 137.0 13 23 30 NA
[0199] Dyp-cresol glucuronide - 290.0 114.8 113.1 21 30 21 NA
[0200] Table represents results of mass spectrometry optimizing conditions for the named metabolites, *Confirming ion; Quantifying ion, MRM ^Multiple reaction monitoring; NA= not applicable; CE = collision energy; m / z. = mass over charge ratio.
[0201] The following ion source parameters were applied: nebulizing gas flow, 3 L / min; heating gas flow, 10 L / min; interface temperature, 300 °C; desolvation line temperature, 250
[0202] °C; heat block temperature, 400°C; and drying gas flow, 10 L / min. For data analysis software Lab Solution (Shimadzu) was used. Phenylpyruvic acid and phenylacrylglycine were analyzed in n=2,140, benzoic acid in n=2,379, and indoleactylglutmaine (lAGln) in n=l,978 sequential subjects. Data for PAGln in the GeneBank cohort presented here were previously published1, and are used here for comparative analysis.
[0203] LC-MS / MS analysis of aromatic amino acids in plasma
[0204] Internal standards pre-mixed with methanol (13Ce-Phe, u-Tyr and Ds-Trp; 100 pl) along with pure, ice cold methanol (800 pl) were added to plasma (20 pl), followed by vortexing and centrifuging (21,000 x g; 4 °C for 15 min). The clear supernatant (800 pl) was transferred to a glass borosilicate tube (12x75 mm) and completely dried in a speedvac under vacuum. After drying, n-butanol containing 5% HC1 (100 pl) was added and samples were covered, vortexed and heated for 1 h at 80 °C. After esterification, samples were cooled to room temperature and excess n-butanol and HC1 was removed in a nitrogen evaporator. Dry residue was dissolved in methanol and water (50:50; v / v; 100 pl) and transferred to glass vials with microinserts; 0.2 pl of this solution was used for the LC-MS / MS analysis by using the system and Cl 8 column described above. Solvent A (10 mM ammonium acetate and 0.125% acetic acid in water) and B (10 mM ammonium acetate and 0.125% acetic acid in acetonitrile:water (95:5, v / v) were run using the following gradient: 0.0 min (0% B); 0.0-2.0 min (0% B); 2.0-5.0 min (0%B^20%B); 5.0-6.0 min (20%B^60%B); 6.0-7.5 min (60%B^70%B); 7.5-8.0 min (70%B^ 100%B); 8.0-9.5 min (100%); 9.5-10 min (100%B->0%B); 10.0-15.0 min (0% B) with a flow rate of 0.4 mL / min. Electrospray ionization in positive mode with multiple reaction monitoring (MRM) was used with the following transitions: m / z. 220.00^120.15 for phenylalanine butyl ester; m / z. 228.00^ 126.15 for13C6-phenylalanine butyl ester; m / z 230.00^136.10 for tyrosine butyl ester; m / z 249.20^ 145.05 for u-tyrosine butyl ester; m / z 261.00^244.15 for tryptophan butyl ester and m / z 265.10-^248.20 for Ds-tryptophan butyl ester. The amino acids Phe, Tyr and Trp were analyzed in 2,159 sequential subjects in GeneBank.
[0205] Mouse antibiotic treatment
[0206] To test the impact of gut microbes on selected metabolites levels 8 week old C57BL / 6J mice (n=15 males and n=15 females; #000664; Jackson Laboratory Bar Harbor, Maine). Animals were maintained on chow diet (Teklad Global Rodent Rodent Diet2018; Envigo Indianapolis, IN) in micro-isolator cages with a 14 h / 10 h light / dark cycle. Following baseline blood draw, mice were treated for 5 days with a cocktail of antibiotics (provided in drinking water) previously shown to suppress gut microbiota2. Cages were changed every day. A second blood collection was performed at the end of antibiotics treatment. Mice then underwent a one week recolonization period, during which time standard drinking water was provided and fecal pellets from conventionally raised mice of the same age and sex were added to their cages. A third blood sample was collected after this period.
[0207] Statistics
[0208] The Wilcoxon rank sum test or Student’s t-test for continuous variables and chi- square test for categorical variables were used to examine the difference between groups. Cox proportional hazards analysis was used to determine Hazard ratio (HR) and 95% confidence intervals (95% CI) for MACE and all-cause mortality stratified according to metabolite level quartiles [Quartile 4 (Q4) vs Quartile 1 (QI)]. Adjustments were made for age, sex, smoking status, systolic blood pressure (SBP) and diastolic blood pressure (DBP) or hypertension, low-density lipoprotein cholesterol (LDL), high-density lipoprotein cholesterol (HDL), triglycerides (TG), high sensitivity C-reactive protein (hsCRP) and diabetes. Spearman's correlation was used to examine the associations among metabolites. Differences among metabolites levels before, during and after antibiotics (Abx) treatment were calculated by non-parametric one-way ANOVA (Kruskal Wallis). All analysis was performed with RStudio-R version 4.1.3. (2022-03-10) (Vienna, Austria), or GraphPad Prism 9. A P- value of <0.05 was considered statistically significant.
[0209] Additional statistical analysis
[0210] Cox proportional hazards analysis was used to determine Hazard ratio (HR) and 95% confidence intervals (95% CI) for MACE and all-cause mortality stratified according to metabolite level quartiles [Quartile 4 (Q4) vs Quartile 1 (Qi )]. Adjustments were made for age, sex, smoking status, systolic blood pressure (SBP) and diastolic blood pressure (DBP) or hypertension, low-density lipoprotein cholesterol (LDL), high-density lipoprotein cholesterol (HDL), triglycerides (TG), high sensitivity C-reactive protein (hsCRP), diabetes, history of atrial fibrillation, medications for cardiometabolic diseases, alcohol consumption and education. The latter was sued for the US cohort only. All analysis was performed with RStudio-R version 4.1.3. (2022-03-10) (Vienna, Austria), or GraphPad Prism 9. A P-value of <0.05 was considered statistically significant. RESULTS
[0211] Gut microbe generated metabolites of aromatic amino acids and their association with incident adverse cardiac event risks.
[0212] We began by assembling a comprehensive list of candidate metabolites, and subsequently developed stable isotope dilution LC-MS / MS methods for their quantitation, differentiating candidates from structural isomers where necessary. Only metabolites that were detected in over three quarters of fasting plasma samples and had reproducible values in quality control samples (included at beginning, middle and end of every batch, typically n=81 samples per batch, of samples analyzed) over the course of the study (CV<20%) were included for further analysis.
[0213] To asses which metabolites were indeed linked to gut microbial metabolism, we next explored whether suppression of gut microbiota with poorly absorbed cocktail of oral antibiotics could reduce plasma levels of the metabolites in humans and in mice (Figures 7- 11). Briefly, healthy control subjects were placed on oral cocktail of poorly absorbed antibiotics. The impact of 7 days of antibiotic suppression on metabolite levels was assessed both at fasting and at multiple post prandial time points as described in Methods. Gut microbiota suppression studies were also performed on mice. (Figures 9 and 11). In parallel, levels of compounds potently resulting from gut microbial fermentation of aromatic amino acid were examined for their associations with incident adverse cardiovascular event risks and all-cause mortality. For these studies, we utilized two independent clinical cohorts composed of sequential individuals undergoing elective diagnostic cardiac evaluation with longitudinal follow up (a US Cohort, GeneBank (n=4,000); and a European Cohort, LipidCardio (n=833); Methods). The overall associations observed between metabolite levels and adverse outcomes within each cohort were highly similar; consequently, analyses presented herein are for the combined cohort, with results for the individual cohorts presented in other Tables. Baseline clinical and laboratory characteristics of the combined cohort (n=4,833) are summarized in Table 4.
[0214] TABLE 4
[0215] US cohort European
[0216] (GeneBank) (LipidCardio)
[0217] Characteristics (n=4,000) (n=833)
[0218] Age (years) 63.1 (55.0-71.6) 75.0 (66.0-81.0)
[0219] Sex male (%) 64.5 70.1
[0220] Diabetes mellitus (%) 31.5 27.9
[0221] Hypertension (%) 38.8 80.4 Smoking (%) 12.7 16.8
[0222] CAD (%) 77.7 69.3
[0223] MACE (3 years; %) 12.9 23.5
[0224] HDL cholesterol (mg / dL) 34.1 (28.3-41.2) 48.0 (39.0-60.0)
[0225] LDL cholesterol (mg / dL) 96.0 (78.0-117.0) 91.5 (69.0-122.0)
[0226] TG (mg / dL) 118.0 (85.0-170.0) 119.0 (104.0-146.0)
[0227] C-reactive protein (mg / L) 2.43 (1.04-5.93) 1.90 (0.80-5.10) eGFR (ml / min / 1.73 m2) 91.0 (75.8-100.3) 74.0 (60.3-90.7)
[0228] Education level (%) (College) 46.2 32.7*
[0229] History of atrial fibrillation (%) 12.5 27.5
[0230] Alcohol consumption (%) 44.3 54.7
[0231] Baseline medications
[0232] Anti-hypertensive medications (%) 86.0 82.6
[0233] ACE inhibitors (%) 50.1 70.6
[0234] Beta blocker (%) 63.1 58.6
[0235] Calcium channel blocker (%) 19.7 N.A.
[0236] Diuretics (%) 21.1 N.A.
[0237] Antiplatelet / Antithrombotic medication (%) 73.8 60.3
[0238] Aspirin (%) 73.8 55.8
[0239] Other (%) 0.2 20.5
[0240] Lipid lowering medication (%) 64.3 59.7
[0241] Statins (%) 60.2 59.7
[0242] Other (%) 13.0 N.A.
[0243] Antidiabetic medication (%) 17.3 N.A.
[0244] Subjects were from both US (GeneBank) and European (LipidCardio) cohorts, both of which were composed of sequential stable subjects without evidence of acute coronary syndrome or positive troponin test who underwent elective diagnostic coronary angiography (cardiac catheterization or coronary computed tomography) for evaluation of coronary artery disease (CAD). MACE was defined as death, nonfatal myocardial infarction), or nonfatal cerebrovascular accident (stroke) following enrollment. Continuous data are presented as median (interquartile range), categorical variables are presented as %; ACE angiotensinconverting enzyme, eGFR = estimated glomerular filtration rate was calculated on the basis of the Chronic Kidney Disease Epidemiology Collaboration 2021 CKD-EPI Creatinine equation.19Alcohol consumption (%) represents proportion of subjects stating they drink >1 alcoholic beverage / d. HDL high-density lipoprotein, LDL low-density lipoprotein. N.A., not available. *Results shown are for total of 434 subjects with known education level.
[0245] The cohort was made by merging individuals from the GeneBank (US cohort (n=4,000)) and LipidCardio (European cohort (n=833)), which is composed of sequential stable subjects without evidence of acute coronary syndrome (cardiac troponin I<0.03 ng / ml) who underwent elective diagnostic coronary angiography (cardiac catheterization or coronary computed tomography) for evaluation of coronary artery disease (CAD). MACE was defined as death, nonfatal myocardial infarction (MI), or nonfatal cerebrovascular accident (stroke) following enrollment. Continuous data are presented as median (interquartile range), categorical variables 2 are presented as %; ACE angiotensin-converting enzyme, eGFR = estimated glomerular filtration rate. HDL high-density lipoprotein, hsCRP high-sensitivity C- reactive protein, LDL low-density lipoprotein.
[0246] The combined cohort had more males (65.4%), a median age of 64.9 years, and 14.7% of subjects experienced an incident adjudicated major adverse cardiac event (MACE; defined as non-fatal myocardial infarction, non-fatal stroke or death) during 3 years of follow up. When examining each analyte for its association with incident MACE risk, the distribution of each analyte quantified in both the merged and individual cohorts are shown in Tables 5-8, with results (hazard ratio (HR) and 95% confidence intervals (CI)) stratified by whether the subjects experienced an incident MACE event during follow-up (3 yr) (Figure 1; Figures 12 and 13 for HR of each compound in each of the individual cohorts).
[0247] Table 5. Distribution of baseline levels of select aromatic amino acid (AAA) gut microbiota-derived metabolites in combined US (GeneBank) and European (LipidCardio) cohorts stratified by MACE.
[0248] AU subjects Control (No-MACE) MACE
[0249] Metabolite (n=4,833) (n=4,123) (n=710) P*
[0250] Median (IQR) (pM) Median (IQR) (jiM) Median (IQR) (jiM)
[0251] Phenylalanine (Phe) 57.54 (50.98; 64.65) 57.53 (51.13; 64.68) 57.61 (50.29; 64.51) 0.711
[0252] PAGln 2.95 (1.80; 4.76) 2.83 (1.74; 4.48) 4.00 (2.35; 6.90) <0.001
[0253] PAGly 0.001 (0.0005; 0.003) 0.001 (0.0005; 0.003) 0.001 (0.0005; 0.005) <0.001
[0254] Phenylacetic acid 0.43 (0.18; 0.78) 0.42 (0.17; 0.76) 0.51 (0.25; 0.90) <0.001
[0255] Hippuric acid 5.60 (2.55; 9.31) 5.48 (2.46; 8.99) 6.74 (3.28; 10.63) <0.001
[0256] Benzoic acid 1.32 (0.13; 2.72) 1.32 (0.13; 2.72) 1.35 (0.13; 2.72) 0.524
[0257] Phenylacryl glycine 0.03 (0.01; 0.06) 0.03 (0.01; 0.06) 0.04 (0.01; 0.08) 0.002
[0258] Phenylpyruvic acid 0.49 (0.36; 0.66) 0.49 (0.36; 0.66) 0.50 (0.37; 0.67) 0.282
[0259] Tyrosine (Tyr) 60.58 (51.60; 71.65) 60.88 (52.13; 71.98) 58.28 (48.76; 69.97) 0.003 p-Cresol gulcuronide 0.11 (0.04; 0.24) 0.11 (0.04; 0.23) 0.15 (0.06; 0.38) <0.001 p-Cresol sulfate 18.16 (10.12; 30.12) 17.55 (9.82; 28.87) 23.17 (12.08; 39.93) <0.001
[0260] 4-OH-Phenyllactic acid 0.83 (0.63; 1.08) 0.82 (0.63; 1.05) 0.90 (0.68; 1.24) <0.001
[0261] 4-Ethylphenylsulfate 0.02 (0.01; 0.05) 0.02 (0.01 ; 0.05) 0.03 (0.01 ; 0.05) 0.049 4-OH-Benzoic acid 0.26 (0.20; 0.41) 0.26 (0.20; 0.41) 0.27 (0.22; 0.45) 0.007
[0262] 4-OH-Hippuric acid 0.13 (0.07; 0.26) 0.12 (0.06; 0.24) 0.18 (0.09; 0.36) <0.001
[0263] 2-OH-Hippuric acid 1.92 (0.10; 5.44) 1.90 (0.12; 5.28) 1.95 (0.04; 6.29) 0.456
[0264] 3-OH-Hippuric acid 0.07 (0.02; 0.21) 0.07 (0.02; 0.21) 0.08 (0.02; 0.27) 0.003
[0265] 2-OH-Benzoic acid 15.78 (0.69; 61.36) 16.54 (0.95; 61.58) 10.91 (0.23; 57.55) 0.002
[0266] Tryptophan (Trp) 45.76 (37.42; 55.03) 45.89 (37.72; 55.28) 45.29 (35.17; 52.62) 0.004
[0267] Indole glucuronide 0.009 (0.001; 0.025) 0.008 (0.0005; 0.023) 0.016 (0.0005; 0.042) <0.001
[0268] Indoxyl sulfate 3.20 (1.98; 5.05) 3.11 (1.94; 4.84) 3.92 (2.33; 6.34) <0.001
[0269] 5-OH-indole-3-acetic 0.05 (0.04; 0.07) 0.05 (0.04; 0.07) 0.06 (0.04; 0.09) <0.001 acid
[0270] Indole-3-acetyl glutamine 0.01 (0.01; 0.03) 0.01 (0.01 ; 0.03) 0.02 (0.01 ; 0.04) <0.001
[0271] Serotonin 0.05 (0.02; 0.33) 0.05 (0.02; 0.34) 0.05 (0.02; 0.30) 0.09
[0272] Indole-3-acetic acid 1.25 (0.85; 1.83) 1.24 (0.85; 1.81) 1.27 (0.84; 1.92) 0.404
[0273] Indole-3-propionic acid 0.47 (0.26; 0.78) 0.48 (0.26; 0.79) 0.45 (0.26; 0.73) 0.051
[0274] Indole-3-lactic acid 0.58 (0.43; 0.79) 0.57 (0.43; 0.77) 0.63 (0.45; 0.87) <0.001
[0275] A-Acetyl-tryptophan 0.01 (0.01; 0.02) 0.01 (0.01; 0.02) 0.02 (0.01; 0.02) <0.001
[0276] Median and interquartile range concentrations of selected metabolites in individuals undergoing elective diagnostic cardiac evaluation with longitudinal follow-up in combined GeneBank and LipidCardio cohorts, and Wilcoxon rank sum test P value for Yes / No to MACE over ensuing 3 years of follow-up. *P values were calculated with Wilcoxon sum rank test; IQR=interquartile range (25thand 75thpercentile); MACE - major adverse cardiac events (MACE: myocardial infarction, stoke or death); Note: Amino acids Phe, Tyr and Trp were analyzed in 2,159 sequential subjects, phenylpyruvic acid and phenylacrylglycine in 2,140 sequential subjects, benzoic acid in 2,379 while indole-3-actyl glutmaine in 1,978 sequential subjects. Data for PAGln (US, GeneBank cohort) presented here were previously published1and here are used for comparative analysis.
[0277] Table 6. Distribution of baseline levels of select AAA gut microbiota-derived metabolites in US (GeneBank) cohort stratified by MACE.
[0278] All subjects Control (No-MACE) MACE
[0279] Metabolite (n=4,000) (n=3,486) (n=514) P*
[0280] Median (IQR) (pM)
[0281] Median (IQR) (pM) Median (IQR) (pM)
[0282] Phenylalanine (Phe) 58.80 (52.87; 65.61) 58.63 (52.94; 65.52) 59.96 (52.30, 66.16) 0.333
[0283] Phenylpyruvic acid 0.48 (0.36; 0.62) 0.48 (0.36; 0.62) 0.47 (0.35; 0.61) 0.576
[0284] Phenylacetic acid 0.44 (0.17; 0.82) 0.43 (0.16; 0.80) 0.54 (0.22; 0.96) <0.001 PAGln 3.01(1.83; 4.89) 2.90 (1.77; 4.64) 4.03 (2.34; 7.17) <0.001
[0285] PAGly 0.001(0.001; 0.003) 0.001 (0.001; 0.003) 0.001 (0.001; 0.005) <0.001
[0286] Phenylacryl glycine 0.03 (0.01 ; 0.06) 0.03 (0.01; 0.06) 0.03 (0.01; 0.07) 0.232
[0287] Benzoic acid 1.47 (0.03; 2.79 ) 1.47 (0.03; 2.81) 1.44 (0.07; 2.76) 0.806
[0288] Hippuric acid 5.63 (2.47; 9.26) 5.55 (2.40; 9.06) 6.42 (3.16; 10.08) 0.001
[0289] Tyrosine (Tyr) 61.93 (53.26; 72.70) 61.95 (53.49; 72.72) 61.77 (50.90; 72.21) 0.224 p-Cresol gulcuronide 0.12 (0.05; 0.26) 0.12 (0.05; 0.24) 0.16 (0.06; 0.42) <0.001 p-Cresol sulfate (pCS) 18.87 (10.66; 31.22) 18.32 (10.39; 30.15) 23.46 (12.54; 41.69) <0.001
[0290] 4-OH-Phenyllactic 0.83 (0.65; 1.06) 0.82 (0.64; 1.04) 0.90 (0.71; 1.23) <0.001 acid
[0291] 4-Ethylphenylsulfate 0.02 (0.01 ; 0.05) 0.02 (0.01; 0.05) 0.03 (0.01; 0.06) 0.088
[0292] 4-OH-Bcnzoic acid 0.28 (0.21; 0.47) 0.28 (0.21; 0.46) 0.31 (0.23; 0.58) <0.001
[0293] 4-OH-Hippuric acid 0.14 (0.07; 0.29) 0.13 (0.07; 0.27) 0.20 (0.10; 0.46) <0.001
[0294] 2-OH-Hippuric acid 2.46 (0.24; 6.35) 2.41 (0.26; 6.16) 3.21 (0.11; 8.00) 0.033
[0295] 3-OH-Hippuric acid 0.08 (0.02; 0.23) 0.07 (0.02; 0.22) 0.09 (0.02; 0.30) 0.013
[0296] 2-OH-Benzoic acid 21.57 (2.04; 73.34) 21.76 (2.26; 72.36) 20.40 (0.48; 81.03) 0.378
[0297] Tryptophan (Trp) 43.69 (35.98; 51.73) 43.94 (36.27; 52.05) 40.29 (32.21; 47.85) <0.001
[0298] Indole glucuronide 0.01 (0.001; 0.026) 0.01 (0.001; 0.024) 0.02 (0.004; 0.042) <0.001
[0299] Indoxyl sulfate (IS) 3.32 (2.03; 5.18) 3.26 (1.99; 5.04) 4.01 (2.35; 6.42) <0.001
[0300] 5-OH-indole-3-acetic 0.06 (0.04; 0.08) 0.05 (0.04; 0.07) 0.07 (0.05; 0.10) <0.001 acid
[0301] Indole-3-acetyl 0.02 (0.01 ; 0.03) 0.01 (0.01 ; 0.03) 0.02 (0.01 ; 0.04) <0.001 glutamine
[0302] Serotonin 0.09 (0.03; 0.40) 0.09 (0.03; 0.39) 0.12 (0.03; 0.43) 0.044
[0303] Indole-3-acetic acid 1.31 (0.92; 1.91) 1.31 (0.92; 1.89) 1.42 (0.91; 2.05) 0.053
[0304] Indole-3-propionic 0.46 (0.25; 0.78) 0.47 (0.25; 0.78) 0.43 (0.24; 0.72) 0.033 acid
[0305] Indole-3-lactic acid 0.59 (0.43; 0.80) 0.58 (0.43; 0.79) 0.63 (0.46; 0.88) <0.001
[0306] N- Acetyl-tryptophan 0.01 (0.01; 0.02) 0.01 (0.01; 0.02) 0.01 (0.01; 0.02) 0.031
[0307] Median and interquartile range concentrations of selected metabolites in the US cohort (GeneBank), and Wilcoxon signed rank test P value for Yes / No to MACE over ensuing 3 years of follow-up. *P values were calculated with Wilcoxon sum rank test; IQR=interquartile range (25thand 75thpercentile); MACE - major adverse cardiac events (MACE: myocardial infarction, stoke or death); Note: Amino acids Phe, Tyr and Trp were analyzed in 2,159 sequential subjects, phenylpyruvic acid and phenylacrylglycine in 2,140 sequential subjects, benzoic acid in 2379 while indole-3-actyl glutmaine in 1,978 sequential subjects. Data for PAGln (US cohort) presented here were previously published1and are used for comparative analysis.
[0308] Table 7. Distribution of baseline levels of select AAA gut microbiota-derived metabolites in European (LipidCardio) cohort stratified by MACE.
[0309] All subjects Control (No-MACE) MACE
[0310] Metabolite (n=833) (n=637) (n=196) P*
[0311] Median (IQR) (pM)
[0312] Median (IQR) (pM) Median (IQR) (pM)
[0313] Phenylalanine (Phe) 53.48 (46.92; 61.60) 53.12 (46.52; 61.23) 54.31 (48.29, 62 776) 0.088
[0314] Phenylpyruvic acid 0.55 (0.41; 0.73) 0.55 (0.39; 0.72) 0.55 (0.44, 0.75) 0.230
[0315] Phenylacetic acid 0.39 (0.23; 0.63) 0.37 (0.22; 0.60) 0.47 (0.27, 0.68) 0.001
[0316] PAGln 2.72 (1.72; 4.22) 2.44 (1.58; 3.76) 3.93 (2.48, 6.48) <0.001
[0317] PAGly 0.001 (0.001 ; 0.003) 0.001 (0.001 ; 0.003) 0.001 (0.0005, 0 .005) <0.001
[0318] Phenylacryl glycine 0.04 (0.02; 0.07) 0.03 (0.02; 0.06) 0.04 (0.02, 0.09) 0.001
[0319] Benzoic acid 0.94 (0.13; 2.33) 0.90 (0.13; 2.32) 1.13 (0.13, 2.58) 0.482
[0320] Hippuric acid 5.46 (2.82; 9.57) 5.04 (2.63; 8.93) 7.18 (3.60, 12.57 ') <0.001
[0321] Tyrosine (Tyr) 57.15 (48.24; 68.63) 57.80 (48.44; 68.74) 55.48 (47.30, 68 .51) 0.227 p-Cresol gulcuronide 0.07 (0.03; 0.17) 0.06 (0.02; 0.13) 0.13 (0.05, 0.33) <0.001 p-Cresol sulfate (pCS) 14.82 (8.03; 24.36) 12.92 (7.59; 20.85) 21.77 (10.85, 35 .63) <0.001
[0322] 4-OH-Phenyllactic acid 0.83 (0.56; 1.14) 0.81 (0.56; 1.10) 0.90 (0.58, 1.27) 0.034
[0323] 4-Ethylphenylsulfate 0.02 (0.01; 0.04) 0.02 (0.01; 0.04) 0.02 (0.01, 0.04) 0.054
[0324] 4-OH-Benzoic acid 0.22 (0.20; 0.25) 0.22 (0.19; 0.25) 0.23 (0.20, 0.26) 0.001
[0325] 4-OH-Hippuric acid 0.10 (0.06; 0.17) 0.09 (0.06; 0.15) 0.15 (0.08, 0.23) <0.001
[0326] 2-OH-Hippuric acid 0.45 (0.01; 1.82) 0.40 (0.01; 1.69) 0.70 (0.01, 2.60) 0.002
[0327] 3-OH-Hippuric acid 0.06 (0.02; 0.17) 0.05 (0.02; 0.14) 0.06 (0.03, 0.20) 0.006
[0328] 2-OH-Benzoic acid 3.00 (0.06; 15.85) 2.77 (0.06; 15.49) 4.31 (0.08, 17.8S >) 0.576
[0329] Tryptophan (Trp) 52.20 (42.91; 62.13) 53.46 (43.81; 62.89) 49.38 (40.86, 57 .96) <0.001
[0330] Indole glucuronide 0.007 (0.001 ; 0.019) 0.005 (0.001; 0.015) 0.013 (0.001; 0.1 )4) <0.001
[0331] Indoxyl sulfate (IS) 2.74 (1.80; 4.23) 2.52 (1.75; 3.83) 3.79 (2.19; 6.19) <0.001
[0332] 5-OH-indole-3-acetic 0.04 (0.03; 0.05) 0.04 (0.03; 0.05) 0.05 (0.04; 0.08) <0.001 acid
[0333] Indole-3-acetyl 0.01 (0.01; 0.02) 0.01 (0.01; 0.02) 0.02 (0.01; 0.04) <0.001 glutamine
[0334] Serotonin 0.01 (0.01 ; 0.02) 0.01 (0.01; 0.02) 0.01 (0.01; 0.02) 0.551 Indole-3-acetic acid 0.88 (0.63; 1.39) 0.86 (0.62; 1.33) 0.98 (0.69; 1.50) 0.018
[0335] Indole- 3 -propionic acid 0.51 (0.34; 0.80) 0.51 (0.34; 0.82) 0.48 (0.34; 0.74) 0.215
[0336] Indole-3-lactic acid 0.53 (0.42; 0.69) 0.51 (0.42; 0.67) 0.62 (0.43; 0.82) <0.001
[0337] W-Acetyl-tryptophan 0.02 (0.01; 0.02) 0.02 (0.01; 0.02) 0.02 (0.01; 0.03) 0.005
[0338] Median and interquartile range concentrations of selected metabolites in the European cohort (LipidCardio), and Wilcoxon signed rank test P value for Yes / No to MACE over ensuing 3 years of follow-up. *P values were calculated with Wilcoxon sum rank test; IQR=interquartile range (25thand 75thpercentile); MACE - major adverse cardiac events (MACE: MI, stoke or death).
[0339] Notably, all three aromatic amino acid nutrient precursors (Phe, Tyr, and Trp) had lower circulating levels among individuals with MACE vs those without, but only Tyr and Trp levels reached significance (Table 5). Tyr and Trp showed inverse associations with incident MACE risk, while in each case only a subset of the down-stream metabolites were associated with heightened risk, including following adjustments for comorbidities and CVD risk factors (Figure 1, Figures 12 and 13). The results of analyses (HR of Q4 vs QI and 95% CI) are overlaid on proposed pathway maps of each aromatic amino acid in Figures 2 and 3. Also shown are currently reported microbial enzyme sources, including insights into gut microbiota contribution based on results of the antibiotic suppression intervention studies performed in humans and rodents.
[0340] When mapping the metabolism of each of the dietary aromatic amino acids by gut microbiota, the initial step typically involves removal of the alpha amino group by deaminases, an enzymatic activity that is promiscuous among gut microbiota.55Of note, circulating levels of the proximal deamination product of Phe, phenylpyruvic acid, were not appreciably different among individuals who experienced MACE versus those that did not (Figures 1, 2). Phenylpyruvic acid is further metabolized by either oxidative (forming phenylacetic acid) or reductive (forming phenyllactic acid) metabolism11 34 56. Notably, PAGln and PAGly, downstream metabolites from phenylactetic acid, were associated with incident MACE risk, including following adjustments for traditional CVD risk factors (Figures 1, 2). Products of reductive degradation of phenylpyruvic acid, which terminate in hippuric acid, showed a trend toward increased levels with MACE, and remained significantly associated with incident MACE risk following adjustments (Figures 1, 2).
[0341] A map of gut microbiota dependent catabolism of dietary Tyr metabolites with overlaid associations with incident MACE risks in the combined US and European cohort is also shown in Figure 2. The Tyr derived metabolites that remained associated with MACE risks after adjustments for traditional CVD risk factors were derived either from p-cresol (both pCS and p-cresol glucuronide), 4-OH-phenyllactic acid, or 4-OH-benzoic acid (4-OH- hippuric acid). Notably, while structural isomers of 4-OH-hippuric acid (2-OH and 3-OH isomers) were also included in the analyses, only 4-OH-hippuric acid remained significantly associated with MACE following adjustments (Figures 1, 2).
[0342] Dietary Trp gives rise to a large array of gut microbe-generated metabolites (Figure 3). Circulating levels of this essential amino acid were inversely associated with incident MACE risk (Figures 1 , 3). Upon further examination of Trp metabolites, indole glucuronide, IS, 5-OH-indole-3-acetic acid, indole-3 -acetyl glutamine and indole-3-lactic acid remained significantly associated with incident MACE risk following adjustments.
[0343] We next examined the relationship between fasting plasma levels of each analyte and all-cause mortality (3-year). The distribution of each analyte quantified in both the merged and individual cohorts are shown in Tables 8-10, with mortality risk shown in Figure 4, and overlaid onto proposed metabolic pathways in Figures 5 and 6.
[0344] Table 8. Distribution of baseline levels of select AAA gut microbiota-derived metabolites in combined US (GeneBank) and European (LipidCardio) cohorts stratified by Mortality.
[0345] Metabolite All subjects (n=4,833) Control (No-death) Death (n=378) P*
[0346] Median (IQR) (pM) (n=4,455) Median (IQR) (pM)
[0347] Median (IQR) (pM)
[0348] Phenylalanine (Phe) 57.54 (50.98; 64.65) 57.36 (50.95; 64.56) 59.22 (51.78; 65.51) 0.104
[0349] PAGln 2.95 (1.80; 4.76) 2.87 (1.76; 4.58) 4.48 (2.58; 8.04) <0.001
[0350] PAGly 0.001(0.001; 0.003) 0.001 (0.001; 0.003) 0.002 (0.001; 0.006) <0.001
[0351] Phenylacetic acid 0.43 (0.18; 0.78) 0.42 (0.18; 0.76) 0.54 (0.25; 0.97) <0.001
[0352] Hippuric acid 5.60 (2.55; 9.31) 5.56 (2.50; 9.14) 6.59 (3.27; 10.92) <0.001
[0353] Benzoic acid 1.32 (0.13; 2.72) 1.32 (0.13; 2.72) 1.41 (0.13; 2.73) 0.357
[0354] Phenylacryl glycine 0.03 (0.01 ; 0.06) 0.03 (0.01 ; 0.06) 0.04 (0.01 ; 0.08) 0.016
[0355] Phenylpyruvic acid 0.49 (0.36; 0.66) 0.49 (0.37; 0.66) 0.50 (0.36; 0.68) 0.849
[0356] Tyrosine (Tyr) 60.58 (51.60; 71.65) 60.67 (51.94; 71.63) 57.84 (48.74; 72.18) 0.142 p-Cresol gulcuronide 0.11 (0.04; 0.24) 0.11 (0.04; 0.23) 0.19 (0.08; 0.45) <0.001 p-Cresol sulfate 18.16 (10.12; 30.12) 17.76 (9.89; 29.22) 25.62 (13.07; 46.05) <0.001
[0357] 4-OH-Phenyllactic acid 0.83 (0.63; 1.08) 0.82 (0.63; 1.05) 0.98 (0.72; 1.34) <0.001
[0358] 4-Ethylphenylsulfate 0.02 (0.01; 0.05) 0.02 (0.01; 0.05) 0.03 (0.01; 0.06) 0.013
[0359] 4-OH-Benzoic acid 0.26 (0.20; 0.41) 0.26 (0.20; 0.40) 0.30 (0.22; 0.53) <0.001 4-OH-Hippuric acid 0.13 (0.07; 0.26) 0.12 (0.07; 0.25) 0.23 (0.10; 0.53) <0.001
[0360] 2-OH-Hippuric acid 1.92 (0.10; 5.44) 1.88 (0.11; 5.28) 2.48 (0.04; 7.32) 0.05
[0361] 3-OH-Hippuric acid 0.07 (0.02; 0.21) 0.07 (0.02; 0.21) 0.09 (0.02; 0.31) 0.001
[0362] 2-OH-Benzoic acid 15.78 (0.69; 61.36) 16.10 (0.79; 60.53) 11.02 (0.22; 70.06) 0.182
[0363] Tryptophan (Trp) 45.76 (37.42; 55.03) 45.98 (37.76; 55.23) 42.01 (31.52; 49.97) <0.001
[0364] Indole glucuronide 0.009 (0.001; 0.025) 0.009 (0.001; 0.023) 0. 02 (0.001; 0.051) <0.001
[0365] Indoxyl sulfate 3.20 (1.98; 5.05) 3.14 (1.95; 4.89) 4. 36 (2.38; 6.88) <0.001
[0366] 5-OH-indole-3-acetic 0.05 (0.04; 0.07) 0.05 (0.04; 0.07) 0. 07 (0.05; 0.11) <0.001 acid
[0367] Indole-3-acetyl 0.01 (0.01; 0.03) 0.01 (0.01; 0.03) 0. 02 (0.01; 0.04) <0.001 glutamine
[0368] Serotonin 0.05 (0.02; 0.33) 0.05 (0.02; 0.33) 0. 07 (0.02; 0.35) 0.122
[0369] Indole-3-acetic acid 1.25 (0.85; 1.83) 1.24 (0.85; 1.81) 1. 38 (0.89; 2.03) 0.016
[0370] Indole-3-propionic acid 0.47 (0.26; 0.78) 0.48 (0.26; 0.79) 0. 42 (0.24; 0.68) 0.001
[0371] Indole-3-lactic acid 0.58 (0.43; 0.79) 0.58 (0.43; 0.77) 0. 65 (0.44; 0.94) <0.001
[0372] 7V-Acetyl-tryptophan 0.01 (0.01; 0.02) 0.01 (0.01; 0.02) 0. 02 (0.01; 0.03) 0.002
[0373] Median and interquartile range concentrations of selected metabolites in individuals undergoing elective diagnostic cardiac evaluation with longitudinal follow-up in combined US (GeneBank) and European (LipidCardio) cohort, and Wilcoxon rank sum test P value for Yes / No to all-cause mortality over ensuing 3 years of follow-up. *P value were calculated with Wilcoxon rank sum test; IQR=interquartile range (25thand 75thpercentile).
[0374] Table 9. Distribution of baseline levels of select AAA gut microbiota-derived metabolites in US (GeneBank) cohort stratified by Mortality.
[0375] All subjects Control (No-death) Death
[0376] Metabolite (n=4000) (n=3,683) (n=317) P*
[0377] Median (IQR) (pM) Median (IQR) (pM) Median (IQR) (pM)
[0378] Phenylalanine (Phe) 58.80 (52.87; 65.61) 58.63 (52.88; 65.49) 60.92 (52.74; 67.24) 0.093
[0379] PAGln 3.01 (1.82; 4.89) 2.91 (1.78; 4.67) 4.51 (2.52; 8.37) <0.001
[0380] PAGly 0.001 (0.001; 0.003) 0.001 (0.001; 0.003) 0.002 (0.001; 0.006) <0.001
[0381] Phenylacetic acid 0.44 (0.17; 0.82) 0.43 (0.16; 0.80) 0.54 (0.23; 0.98) <0.001
[0382] Hippuric acid 5.63 (2.47; 9.26) 5.59 (2.41; 9.09) 6.33 (3.20; 10.95) 0.003
[0383] Benzoic acid 1.47 (0.03; 2.79) 1.47 (0.03; 2.79) 1.42 (0.29; 2.85) 0.601
[0384] Phenylacryl glycine 0.03 (0.01; 0.06) 0.03 (0.01; 0.06) 0.03 (0.01; 0.08) 0.175
[0385] Phcnylpyruvic acid 0.48 (0.36; 0.62) 0.48 (0.36; 0.62) 0.48 (0.34; 0.64) 0.975 Tyrosine (Tyr) 61.93 (53.26; 72.70) 62.06 (53.55; 72.68) 58.61 (48.63; 73.20) 0.067 p-Cresol gulcuronide 0.12 (0.05; 0.26) 0.12 (0.05; 0.25) 0.20 (0.08; 0.48) <0.001 p-Cresol sulfate 18.87 (10.66; 31.22) 18.43 (10.44; 30.22) 26.03 (13.68; 46.14) <0.001
[0386] 4-OH-Phenyllactic acid 0.83 (0.65; 1.06) 0.82 (0.64; 1.04) 0.97 (0.74; 1.31) <0.001
[0387] 4-Ethylphenylsulfate 0.02 (0.01; 0.05) 0.02 (0.01; 0.05) 0.03 (0.01; 0.07) 0.007
[0388] 4-OH-Benzoic acid 0.28 (0.21; 0.47) 0.28 (0.21; 0.46) 0.32 (0.23; 0.65) <0.001
[0389] 4-OH-Hippuric acid 0.14 (0.07; 0.29) 0.13 (0.07; 0.27) 0.25 (0.11; 0.58) <0.001
[0390] 2-OH-Hippuric acid 2.46 (0.24; 6.35) 2.43 (0.26; 6.21) 3.14 (0.05; 8.57) 0.148
[0391] 3-OH-Hippuric acid 0.08 (0.02; 0.23) 0.07 (0.02; 0.22) 0.10 (0.02; 0.36) 0.001
[0392] 2-OH-Benzoic acid 21.57 (2.04; 73.34) 21.95 (2.24; 72.72) 15.17 (0.29; 78.70) 0.086
[0393] Tryptophan (Trp) 43.69 (35.98; 51.73) 43.94 (36.28; 52.00) 38.31 (30.72; 47.27) <0.001
[0394] Indole glucuronide 0.01 (0.001; 0.026) 0.009 (0.001; 0.024) 0.021 (0.001; 0.051) <0.001
[0395] Indoxyl sulfate 3.32 (2.03; 5.18) 3.27 (2.01; 5.04) 4.45 (2.40; 7.14) <0.001
[0396] 5-OH-indole-3-acetic 0.06 (0.04; 0.08) 0.05 (0.04; 0.07) 0.08 (0.05; 0.11) <0.001 acid
[0397] Indole-3-acetyl 0.02 (0.01; 0.03) 0.01 (0.01; 0.03) 0.02 (0.01; 0.04) <0.001 glutamine
[0398] Serotonin 0.09 (0.03; 0.40) 0.09 (0.03; 0.40) 0.13 (0.03; 0.41) 0.134
[0399] Indole-3-acetic acid 1.31 (0.92; 1.91) 1.31 (0.92; 1.89) 1.43 (0.92; 2.10) 0.042
[0400] Indole-3-propionic acid 0.46 (0.25; 0.78) 0.47 (0.25; 0.79) 0.42 (0.23; 0.67) 0.003
[0401] Indole-3-lactic acid 0.59 (0.43; 0.80) 0.59 (0.43; 0.79) 0.67 (0.46; 0.95) <0.001
[0402] (V-Acetyl-tryptophan 0.01 (0.01 ; 0.02) 0.01 (0.01 ; 0.02) 0.01 (0.01 ; 0.03) 0.004
[0403] Median and interquartile range concentrations of selected metabolites in individuals undergoing elective diagnostic cardiac evaluation with longitudinal follow up in the US cohort (GeneBank), and Wilcoxon rank sum test P value for Yes / No to all-cause mortality over the ensuing 3 years of follow-up. *P value were calculated with Wilcoxon rank sum test; IQR=interquartile range (25thand 75thpercentile);
[0404] Table 10. Distribution of baseline levels of select AAA gut microbiota-derived metabolites in European (LipidCardio) cohort stratified by Mortality.
[0405] Phenylalanine (Phe) 53.48 (46.92; 61.60) 53.45 (46.87; 61.52) 54.32 (48.99; 62.48) 0.327
[0406] PAGln 2.72 (1.72; 4.22) 2.61 (1.65; 4.02) 4.42 (2.78; 6.55) <0.001
[0407] PAGly 0.001 (0.001; 0.003) 0.001 (0.001; 0.003) 0.002(0.001; 0.006) 0.009 Phenylacetic acid 0.39 (0.23; 0.63) 0.38 (0.23; 0.62) 0.52 (0.28; 0.78) 0.007
[0408] Hippuric acid 5.46 (2.82; 9.57) 5.39 (2.73; 9.47) 7.89 (3.55; 10.77) 0.034
[0409] Benzoic acid 0.94 (0.13; 2.33) 0.93 (0.13; 2.33) 1.38 (0.13; 2.59) 0.36
[0410] Phenylacryl glycine 0.04 (0.02; 0.07) 0.04 (0.02; 0.07) 0.05 (0.03; 0.10) 0.006
[0411] Phenylpyruvic acid 0.55 (0.41; 0.73) 0.55 (0.40; 0.73) 0.56 (0.47; 0.70) 0.462
[0412] Tyrosine (Tyr) 57.15 (48.24; 68.63) 57.14 (48.24; 68.23) 57.18 (49.09; 71.45) 0.787 p-Cresol gulcuronide 0.07 (0.03; 0.17) 0.07 (0.03; 0.15) 0.15 (0.06; 0.35) <0.001 p-Cresol sulfate 14.82 (8.03; 24.36) 14.16 (7.84; 23.36) 22.46 (10.85; 43.87) <0.001
[0413] 4-OH-Phenyllactic acid 0.83 (0.56; 1.14) 0.82 (0.56; 1.12) 1.02 (0.55; 1.40) 0.054
[0414] 4-Ethylphenylsulfate 0.02 (0.01; 0.04) 0.02 (0.01; 0.04) 0.02 (0.01; 0.04) 0.852
[0415] 4-OH-Benzoic acid 0.22 (0.20; 0.25) 0.22 (0.20; 0.25) 0.24 (0.21; 0.26) 0.021
[0416] 4-OH-Hippuric acid 0.10 (0.06; 0.17) 0.10 (0.06; 0.16) 0.15 (0.08; 0.24) 0.001
[0417] 2-OH-Hippuric acid 0.45 (0.01; 1.82) 0.44 (0.01; 1.78) 0.70 (0.02; 3.03) 0.041
[0418] 3-OH-Hippuric acid 0.06 (0.02; 0.17) 0.06 (0.02; 0.16) 0.06 (0.03; 0.18) 0.529
[0419] 2-OH-Benzoic acid 3.00 (0.06; 15.85) 2.95 (0.06; 15.50) 4.14 (0.08; 19.17) 0.416
[0420] Tryptophan (Trp) 52.20 (42.91; 62.13) 52.47 (42.93; 62.40) 48.27 (42.64; 56.77) 0.017
[0421] Indole glucuronide 0.007 (0.001; 0.019) 0.006 (0.001; 0.018) 0.02 (0.001; 0.047) <0.001
[0422] Indoxyl sulfate 2.74 (1.80; 4.23) 2.69 (1.78; 4.10) 3.61 (2.24; 6.30) 0.001
[0423] 5-OH-indole-3-acetic acid 0.04 (0.03; 0.05) 0.04 (0.03; 0.05) 0.06 (0.04; 0.08) <0.001
[0424] Indole-3-acetyl glutamine 0.01 (0.01; 0.02) 0.01 (0.01; 0.02) 0.02 (0.01; 0.04) 0.015
[0425] Serotonin 0.01 (0.01; 0.02) 0.01 (0.01; 0.02) 0.01 (0.01; 0.02) 0.126
[0426] Indole-3-acetic acid 0.88 (0.63; 1.39) 0.88 (0.63; 1.38) 1.03 (0.69; 1.53) 0.183
[0427] Indole-3-propionic acid 0.51 (0.34; 0.80) 0.51 (0.34; 0.80) 0.46 (0.28; 0.80) 0.264
[0428] Indole-3-lactic acid 0.53 (0.42; 0.69) 0.53 (0.42; 0.69) 0.58 (0.40; 0.83) 0.283
[0429] 7V-Acetyl-tryptophan 0.02 (0.01; 0.02) 0.02 (0.01; 0.02) 0.02 (0.01; 0.03) 0.233
[0430] Median and interquartile range concentrations of selected metabolites in individuals undergoing elective diagnostic cardiac evaluation with longitudinal follow up in the European cohort (LipidCardio), and Wilcoxon rank sum test P value for Yes / No to all-cause mortality over ensuing 3 years of follow-up. *P value were calculated with Wilcoxon rank sum test; IQR=interquartile range (25thand 75thpercentile).
[0431] Associations among metabolites and mortality risk followed trends notably similar to those observed for incident MACE risk, with some modest exceptions. Notably, circulating levels of the aromatic amino acid Tyr were not negatively associated with over-all mortality risk, but its gut microbial metabolite 4-ethylphenyl sulfate, a metabolite reportedly linked to neurocognitive impairment,57did show positive association with incident death risk. Additionally, hippuric acid showed an attenuated association with poorer survival following adjustments, while the Trp metabolite I3PA remained negatively associated with all-cause mortality following adjustments (Figures 4-6).
[0432] As more and more microbial metabolites are shown to contribute to disease-relevant phenotypes, enhanced interest in modifying the functional metabolic output of the gut- microbial community is emerging as a potential therapeutic approach for treating multiple diseases.17, 58Moreover, providing gut microbiome-relevant supplements as therapeutic agents has had beneficial effects on cholesterol levels in animal models, and in randomized, double-blinded, placebo-controlled human intervention trials59. But in order to design personalized therapeutic strategies that target gut microbiota driven pathways, either as a non-lethal bacterial enzyme inhibitors16, 17, 20, 23-27-60Or newly emerging phage therapies61, we first need a comprehensive understanding of both gut microbial metabolism and the relationship between systemic levels of metabolites and incident CVD risks. If we inhibit a specific gut microbial pathway, the “flow of carbon” through the microbial community will be shifted and diverted to alternative end metabolites. Whether these alternative metabolites are associated with benign or harmful outcomes, is important information for informed therapeutics development. Thus, for precision medicine targeting of the gut microbiome both overall metabolic pathways, and whether a given structurally specific metabolite is associated with incident CVD risks, and thus appropriate for further mechanistic studies. The present studies provide a metabolic roadmap of aromatic amino acid metabolites, emphasizing direct experimentally-observed gut microbial contribution to their circulating levels, and their association with incident CVD adverse event risks in both US and European cohorts.
[0433] Some major conclusions noted by the present Example and pathway analyses are that multiple final products of microbial fermentation of Phe and Tyr via oxidative pathways (PAGln, PAGly, pCS and p-cresol glucuronide) are associated with MACE and mortality risk in human subjects. It is of interest that each of these metabolites have previously been shown to affect platelet function and thrombosis potential both in vitro and in vivo.11, 42, 43Additionally, the strong correlations observed between PAGln vs pCS and p-cresol glucuronide in the present studies supports a commonality in their metabolic pathway origins. Also, it is notable that all of these metabolites are almost exclusively of microbial origin, with dramatic suppression of their circulating levels with poorly absorbed antibiotics. The existence of shared microbial metabolic origins suggest the potential for development of therapeutic interventions to inhibit a single pathway, preventing downstream production of numerous MACE-associated metabolites (i.e. diversion of carbon flow in the microbial community toward more “benign” metabolites).
[0434] Trp products associated with MACE (indole glucuronide and IS) are derived from indole, the microbiota-generated metabolite produced by the enzyme trptophanase.35IS has been reported to enhance platelet reactivity, including increased expression of P-selectin, formation of platelet microparticles, platelet-monocyte aggregates45and increases in thrombus formation in animal models of vascular injury41. PAGln, pCS and IS have all been associated with heightened mortality in individuals with renal functional impairment38 40, 62. The present Example show these so-called “uremic toxins” are also associated with incident adverse cardiac event risks among subjects with primarily preserved kidney function (eGFR for the combined cohort, 89 ml / min / 1.73 m2).
[0435] Another conclusion noted from the present Example is that the reductive fermentation (fldH pathway) of Trp produces a metabolite (I3PA) that showed negative association with all-cause mortality, and similar tendency toward inverse association with MACE risk. In previous studies, I3PA has been negatively associated with diet-induced obesity63and both coronary artery calcification and advanced atherosclerosis.64, 65In this Example, the end product from Phe catalyzed by the same microbial pathway, hippurate, was positively associated with MACE, but the positive association with all-cause mortality was attenuated following adjustments for CVD risk factors. Urinary levels of the same metabolite has in cross sectional studies been associated with increased microbial diversity, higher intake of fruit and whole grains, and reduced odds of having metabolic syndrome.50, 51Further, studies have reported that urine hippurate levels are lower in obese individuals,66in T2DM patients,67among those with Crohn’s disease,68and are inversely associated with blood pressure.69Some studies have also reported a positive correlation between plasma hippurate and MACE during follow-up in advanced atherosclerosis cohorts,65as well as increased hippurate excretion in individuals with T2DM.70, 71
[0436] Terminal metabolites generated from Tyr via the reductive gut microbial catabolism branch (4-OH-benzoic acid and 4-OH-hippurate) showed positive associations with MACE risk and death, unlike metabolites derived from Trp and in part from Phe. While other mechanisms can account for this (e.g. differences in their excretion), one non-limiting interpretation of these results is that the metabolites do not share a metabolic origin, and that additional or different gut microbes, microbial enzymes, and / or nutrient precursors (like polyphenols72), may be involved in the production of 4-OH-metabolites.
[0437] Two intermediate products of the Trp and Tyr reductive pathways - indole-3 -lactic acid and 4-OH-phenyllactic acid - were strongly associated with MACE risk and poorer survival. While it has yet to be determined whether these metabolites directly affect cardiovascular health, our experiments using antibiotics to deplete gut bacteria suggest that circulating levels of aromatic lactates are produced primarily via endogenous enzymatic processes (e.g. aromatic a-keto acid reductase and lactic dehydrogenase) within the host (humans), since their levels are not significantly reduced. Alternatively, these metabolites could be produced mainly by antibiotic resistant bacteria and / or fungi in the gut that “bloom” during antibiotic exposure, possibly explaining the modest increases observed in some cases (we also note that increases in levels with antibiotics could signify reduced competition of nutrient precursors by suppression of gut microbiota, leaving more precursor for host absorption). In addition, the strong correlation between circulating levels of 4-OH- phenyllactic acid and indole-3-lactic acid, and the poor correlation between indole-3-lactic acid and KPA further support the possibility that these lactic acids originate from distinct metabolic pathways.
[0438] REFERENCES
[0439] 1. Brown JM, Hazen SL. The gut microbial endocrine organ: Bacterially derived signals driving cardiometabolic diseases. Annu Rev Med. 2015;66:343-359
[0440] 2. Koren O, Spor A, Felin J, Fak F, Stombaugh J, Tremaroli V, et al. Human oral, gut, and plaque microbiota in patients with atherosclerosis. Proc Natl Acad Sci U S A. 2011 ; 108 Suppl 1 :4592-4598
[0441] 3. Tang et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med. 2013;368: 1575-1584
[0442] 4. Yang et al. Gut dysbiosis is linked to hypertension. Hypertension. 2015;65:1331-1340
[0443] 5. Witkowski M, Weeks TL, Hazen SL. Gut microbiota and cardiovascular disease. Circ Res. 2020;127:553-570
[0444] 6. Zhu W, Wang Z, Tang WHW, Hazen SL. Gut microbe-generated trimethylamine n- oxide from dietary choline is prothrombotic in subjects. Circulation. 2017;135:1671-1673
[0445] 7. Koeth et al. Intestinal microbiota metabolism of 1-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med. 2013;19:576-585 8. Skye et al. Microbial transplantation with human gut commensals containing cute is sufficient to transmit enhanced platelet reactivity and thrombosis potential. Circ Res. 2018;123: 1164-1 176
[0446] 9. Zhu W, Gregory JC, Org E, Buffa JA, Gupta N, Wang Z, et al. Gut microbial metabolite tmao enhances platelet hyperreactivity and thrombosis risk. Cell. 2016;165 :111- 124
[0447] 10. Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 201 1 ;472:57-63
[0448] 11. Nemet, et al. A cardiovascular disease- linked gut microbial metabolite acts via adrenergic receptors. Cell. 2020;180:862-877 e822
[0449] 12. Gan XT, Ettinger G, Huang CX, Burton JP, Haist JV, Rajapurohitam V, et al.
[0450] Probiotic administration attenuates myocardial hypertrophy and heart failure after myocardial infarction in the rat. Circ Heart Fail. 2014;7:491-499
[0451] 13. Mayerhofer CCK, Awoyemi AO, Moscavitch SD, Lappegard KT, Hov JR, Aukrust P, et al. Design of the gutheart-targeting gut microbiota to treat heart failure-trial: A phase ii, randomized clinical trial. ESC Heart Fail. 2018;5:977-984
[0452] 14. Costanza AC, Moscavitch SD, Faria Neto HC, Mesquita ET. Probiotic therapy with saccharomyces boulardii for heart failure patients: A randomized, double -blind, placebo- controlled pilot trial. Int J Cardiol. 2015;179:348-350
[0453] 15. Brown JM, Hazen SL. Metaorganismal nutrient metabolism as a basis of cardiovascular disease. Curr Opin Lipidol. 2014;25:48-53
[0454] 16. Wang Z, Roberts AB, Buffa JA, Levison BS, Zhu W, Org E, et al. Non-lethal inhibition of gut microbial trimethylamine production for the treatment of atherosclerosis. Cell. 2015;163: 1585-1595
[0455] 17. Roberts AB, Gu X, Buffa JA, Hurd AG, Wang Z, Zhu W, et al. Development of a gut microbe-targeted nonlethal therapeutic to inhibit thrombosis potential. Nat Med. 2018;24: 1407-1417
[0456] 18. Brown JM, Hazen SL. Targeting of microbe-derived metabolites to improve human health: The next frontier for drug discovery. J Biol Chem. 2017;292:8560-8568
[0457] 19. Witkowski M, Witkowski M, Friebel J, Buffa JA, Li XS, Wang Z, et al. Vascular endothelial tissue factor contributes to trimethylamine n-oxide-enhanced arterial thrombosis. Cardio vase Res. 2021
[0458] 20. Gupta N, Buffa JA, Roberts AB, Sangwan N, Skye SM, Li L, et al. Targeted inhibition of gut microbial trimethylamine n-oxide production reduces renal tubulointerstitial fibrosis and functional impairment in a murine model of chronic kidney disease. Arterioscler Thromb Vase Biol. 2020;40:1239-1255
[0459] 21. Zhang W, Miikeda A, Zuckerman J, Jia X, Charugundla S, Zhou Z, et al. Inhibition of microbiota-dependent tmao production attenuates chronic kidney disease in mice. Sci Rep.
[0460] 2021;l 1:518
[0461] 22. Organ CL, Li Z, Sharp TE, 3rd, Polhemus DJ, Gupta N, Goodchild TT, et al. Nonlethal inhibition of gut microbial trimethylamine n-oxide production improves cardiac function and remodeling in a murine model of heart failure. J Am Heart Assoc. 2020:e016223
[0462] 23. Schugar RC, Gliniak CM, Osborn LJ, Massey W, Sangwan N, Horak A, et al. Gut microbe-targeted choline trimethylamine lyase inhibition improves obesity via rewiring of host circadian rhythms. Elife. 2022; 11
[0463] 24. Adhikari AA, Ramachandran D, Chaudhari SN, Powell CE, Li W, McCurry MD, et al. A gut-restricted lithocholic acid analog as an inhibitor of gut bacterial bile salt hydrolases. ACS Chem Biol. 2021;16:1401-1412
[0464] 25. Adhikari AA, Seegar TCM, Ficarro SB, McCurry MD, Ramachandran D, Yao L, et al. Development of a covalent inhibitor of gut bacterial bile salt hydrolases. Nat Chem Biol. 2020;16:318-326
[0465] 26. Bhatt AP, Pellock SJ, Biemat KA, Walton WG, Wallace BD, Creekmore BC, et al. Targeted inhibition of gut bacterial beta-glucuronidase activity enhances anticancer drug efficacy. Proc Natl Acad Sci U S A. 2020;l 17:7374-7381
[0466] 27. Wallace BD, Wang H, Lane KT, Scott JE, Orans J, Koo JS, et al. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science. 2010;330:831-835
[0467] 28. Levy M, Blacher E, Elinav E. Microbiome, metabolites and host immunity. Curr Opin Microbiol. 2017;35:8-15
[0468] 29. Fischbach MA. Microbiome: Focus on causation and mechanism. Cell. 2018;174:785- 790
[0469] 30. Sonnenburg JL, Backhed F. Diet-microbiota interactions as moderators of human metabolism. Nature. 2016;535:56-64
[0470] 31. Bostick JW, Schonhoff AM, Mazmanian SK. Gut microbiome-mediated regulation of neuroinflammation. Curr Opin Immunol. 2022;76:102177
[0471] 32. Tang WHW, Backhed F, Landmesser U, Hazen SL. Intestinal microbiota in cardiovascular health and disease: Jacc state-of-the-art review. J Am Coll Cardiol. 2019;73:2089-2105 33. Romano KA, Nemet I, Prasad Saha P, Haghikia A, Li XS, Mohan ML, et al. Gut microbiota-generated phenylacetylglutamine and heart failure. Circ Heart Fail.
[0472] 2023;16:e009972
[0473] 34. Zhu Y, Dwidar M, Nemet I, Buffa JA, Sangwan N, Li XS, et al. Two distinct gut microbial pathways contribute to meta-organismal production of phenylacetylglutamine with links to cardiovascular disease. Cell Host Microbe. 2023;31:18-32 el9
[0474] 35. Devlin AS, Marcobal A, Dodd D, Nayfach S, Plummer N, Meyer T, et al. Modulation of a circulating uremic solute via rational genetic manipulation of the gut microbiota. Cell Host Microbe. 2016;20:709-715
[0475] 36. Saito Y, Sato T, Nomoto K, Tsuji H. Identification of phenol- and p-cresol-producing intestinal bacteria by using media supplemented with tyrosine and its metabolites. FEMS Microbiol Ecol. 2018;94
[0476] 37. Aronov PA, Luo FJ, Plummer NS, Quan Z, Holmes S, Hostetter TH, et al. Colonic contribution to uremic solutes. J Am Soc Nephrol. 2011;22:1769-1776
[0477] 38. Lin CJ, Chuang CK, Jayakumar T, Liu HL, Pan CF, Wang TJ, et al. Serum p-cresyl sulfate predicts cardiovascular disease and mortality in elderly hemodialysis patients. Arch Med Sci. 2013;9:662-668
[0478] 39. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351: 1296- 1305
[0479] 40. Ramezani A, Raj DS. The gut microbiome, kidney disease, and targeted interventions. J Am Soc Nephrol. 2014;25:657-670
[0480] 41. Karbowska M, Kaminski TW, Marcinczyk N, Misztal T, Rusak T, Smyk L, et al. The uremic toxin indoxyl sulfate accelerates thrombotic response after vascular injury in animal models. Toxins (Basel). 2017;9
[0481] 42. Gross et al. Para-cresyl sulfate acutely impairs vascular reactivity and induces vascular remodeling. J Cell Physiol. 2015;230:2927-2935
[0482] 43. Pletinck A, Glorieux G, Schepers E, Cohen G, Gondouin B, Van Landschoot M, et al. Protein-bound uremic toxins stimulate crosstalk between leukocytes and vessel wall. J Am Soc Nephrol. 2013;24: 1981-1994
[0483] 44. Chang MC, Chang HH, Chan CP, Yeung SY, Hsien HC, Lin BR, et al. P-cresol affects reactive oxygen species generation, cell cycle arrest, cytotoxicity and inflammation / atherosclerosis-related modulators production in endothelial cells and mononuclear cells. PLoS One. 2014;9:el 14446 45. Yang K, Du C, Wang X, Li F, Xu Y, Wang S, et al. Indoxyl sulfate induces platelet hyperactivity and contributes to chronic kidney disease-associated thrombosis in mice. Blood. 2017;129:2667-2679
[0484] 46. Chitalia VC, Shivanna S, Martorell J, Balcells M, Bosch I, Kolandaivelu K, et al. Uremic serum and solutes increase post- vascular interventional thrombotic risk through altered stability of smooth muscle cell tissue factor. Circulation. 2013;127:365-376
[0485] 47. Bogiatzi C, Gloor G, Allen-Vercoe E, Reid G, Wong RG, Urquhart BL, et al. Metabolic products of the intestinal microbiome and extremes of atherosclerosis. Atherosclerosis. 2018;273:91-97
[0486] 48. Pignanelli M, Bogiatzi C, Gloor G, Allen-Vercoe E, Reid G, Urquhart BL, et al. Moderate renal impairment and toxic metabolites produced by the intestinal microbiome: Dietary implications. J Ren Nutr. 2019;29:55-64
[0487] 49. de Mello VD, Paananen J, Lindstrom J, Lankinen MA, Shi L, Kuusisto J, et al.
[0488] Indolepropionic acid and novel lipid metabolites are associated with a lower risk of type 2 diabetes in the finnish diabetes prevention study. Sci Rep. 2017;7:46337
[0489] 50. Brial F, Chilloux J, Nielsen T, Vieira-Silva S, Falony G, Andrikopoulos P, et al. Human and preclinical studies of the host-gut microbiome co-metabolite hippurate as a marker and mediator of metabolic health. Gut. 2021;70:2105-2114
[0490] 51. Pallister T, Jackson MA, Martin TC, Zierer J, Jennings A, Mohney RP, et al.
[0491] Hippurate as a metabolomic marker of gut microbiome diversity: Modulation by diet and relationship to metabolic syndrome. Sci Rep. 2017;7: 13670
[0492] 52. Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, et al. New creatinine- and cystatin c-based equations to estimate gfr without race. N Engl J Med. 2021 ;385: 1737-1749
[0493] 53. Konig M, Joshi S, Leistner DM, Landmesser U, Sinning D, Steinhagen-Thiessen E, et al. Cohort profile: Role of lipoproteins in cardiovascular disease-the lipidcardio study. BMJ Open. 2019;9:e030097
[0494] 54. Strobe statement— checklist of items that should be included in reports of observational studies (strobe initiative). Int J Public Health. 2008;53:3-4
[0495] 55. Lal PB, Schneider BL, Vu K, Reitzer L. The redundant aminotransferases in lysine and arginine synthesis and the extent of aminotransferase redundancy in escherichia coli. Mol Microbiol. 2014;94:843-856
[0496] 56. Dodd D, Spitzer MH, Van Treuren W, Merrill BD, Hryckowian AJ, Higginbottom SK, et al. A gut bacterial pathway metabolizes aromatic amino acids into nine circulating metabolites. Nature. 2017;551 :648-652 57. Needham BD, Kaddurah-Daouk R, Mazmanian SK. Gut microbial molecules in behavioural and neurodegenerative conditions. Nat Rev Neurosci. 2020;21 :717-731
[0497] 58. Stewart Campbell A, Needham BD, Meyer CR, Tan J, Conrad M, Preston GM, et al. Safety and target engagement of an oral small-molecule sequestrant in adolescents with autism spectrum disorder: An open-label phase lb / 2a trial. Nat Med. 2022;28:528-534
[0498] 59. Haghikia A, Zimmermann F, Schumann P, Jasina A, Roessler J, Schmidt D, et al. Propionate attenuates atherosclerosis by immune-dependent regulation of intestinal cholesterol metabolism. Eur Heart J. 2022;43:518-533
[0499] 60. Haghikia A, Li XS, Liman TG, Bledau N, Schmidt D, Zimmermann F, et al. Gut microbiota-dependent trimethylamine n-oxide predicts risk of cardiovascular events in patients with stroke and is related to proinflammatory monocytes. Arterioscler Thromb Vase Biol. 2018;38:2225-2235
[0500] 61. Federici S, Kredo-Russo S, Valdes-Mas R, Kviatcovsky D, Weinstock E, Matiuhin Y, et al. Targeted suppression of human ibd-associated gut microbiota commensals by phage consortia for treatment of intestinal inflammation. Cell. 2022;185:2879-2898 e2824
[0501] 62. Poesen R, Claes K, Evenepoel P, de Loor H, Augustijns P, Kuypers D, et al. Microbiota-derived phenylacetylglutamine associates with overall mortality and cardiovascular disease in patients with ckd. J Am Soc Nephrol. 2016;27:3479-3487
[0502] 63. Virtue AT, McCright SJ, Wright JM, Jimenez MT, Mowel WK, Kotzin JJ, et al. The gut microbiota regulates white adipose tissue inflammation and obesity via a family of micrornas. Sci Transl Med. 2019;l 1
[0503] 64. Tzoulaki I, Castagne R, Boulange CL, Karaman I, Chekmeneva E, Evangelou E, et al. Serum metabolic signatures of coronary and carotid atherosclerosis and subsequent cardiovascular disease. Eur Heart J. 2019;40:2883-2896
[0504] 65. Cason CA, Dolan KT, Sharma G, Tao M, Kulkami R, Helenowski IB, et al. Plasma microbiome-modulated indole- and phenyl-derived metabolites associate with advanced atherosclerosis and postoperative outcomes. J Vase Surg. 2018;68:1552-1562 el557
[0505] 66. Calvani R, Miccheli A, Capuani G, Tomassini Miccheli A, Puccetti C, Delfini M, et al. Gut microbiome-derived metabolites characterize a peculiar obese urinary metabotype. Int J Obes (Lond). 2010;34:1095-1098
[0506] 67. Salek RM, Maguire ML, Bentley E, Rubtsov DV, Hough T, Cheeseman M, et al. A metabolomic comparison of urinary changes in type 2 diabetes in mouse, rat, and human. Physiol Genomics. 2007;29:99-108 68. Williams HR, Cox IJ, Walker DG, Cobbold JF, Taylor- Robinson SD, Marshall SE, et al. Differences in gut microbial metabolism are responsible for reduced hippurate synthesis in crohn's disease. BMC Gastroenterol. 2010;10: 108
[0507] 69. Holmes E, Loo RL, Stamler J, Bictash M, Yap IK, Chan Q, et al. Human metabolic phenotype diversity and its association with diet and blood pressure. Nature. 2008;453:396- 400
[0508] 70. van Doorn M, Vogels J, Tas A, van Hoogdalem EJ, Burggraaf J, Cohen A, et al. Evaluation of metabolite profiles as biomarkers for the pharmacological effects of thiazolidinediones in type 2 diabetes mellitus patients and healthy volunteers. Br J Clin Pharmacol. 2007;63:562-574
[0509] 71. Messana I, Forni F, Ferrari F, Rossi C, Giardina B, Zuppi C. Proton nuclear magnetic resonance spectral profiles of urine in type ii diabetic patients. Clin Chem. 1998 ;44: 1529- 1534
[0510] 72. Gonthier MP, Cheynier V, Donovan JL, Manach C, Morand C, Mila I, et al. Microbial aromatic acid metabolites formed in the gut account for a major fraction of the polyphenols excreted in urine of rats fed red wine polyphenols. J Nutr. 2003;133:461-467
[0511] 73. Zhang X, Gerard P. Diet- gut microbiota interactions on cardiovascular disease. Comput Struct Biotechnol J. 2022;20:1528-1540
[0512] 74. Shah RV, Steffen LM, Nayor M, Reis JP, Jacobs DR, Allen NB, et al. Dietary metabolic signatures and cardiometabolic risk. Eur Heart J. 2023;44:557-569.
[0513] ADDITIONAL REFERENCES
[0514] 1. Nemet I, Saha PP, Gupta N, Zhu W, Romano KA, Skye SM, Cajka T, Mohan ML, Li L, Wu Y, et al. A Cardiovascular Disease-Linked Gut Microbial Metabolite Acts via Adrenergic Receptors. Cell. 2020;180:862-877 e822.
[0515] 2. Devlin AS, Marcobal A, Dodd D, Nayfach S, Plummer N, Meyer T, Pollard KS, Sonnenburg JL, Fischbach MA. Modulation of a Circulating Uremic Solute via Rational Genetic Manipulation of the Gut Microbiota. Cell Host Microbe. 2016;20:709-715.
[0516] 3. Dodd D, Spitzer MH, Van Treuren W, Merrill BD, Hryckowian AJ, Higginbottom SK, Le A, Cowan TM, Nolan GP, Fischbach MA, et al. A gut bacterial pathway metabolizes aromatic amino acids into nine circulating metabolites. Nature. 2017;551 :648-652.
[0517] 4. Spaapen LJ, Ketting D, Wadman SK, Bruinvis L, Duran M. Urinary D-4- hydroxyphenyllactate, D-phenyllactate and D-2-hydroxyisocaproate, abnormalities of bacterial origin. J Inherit Metab Dis. 1987;10:383-390. 5. Beloborodova N, Bairamov I, Olenin A, Shubina V, Teplova V, Fedotcheva N. Effect of phenolic acids of microbial origin on production of reactive oxygen species in mitochondria and neutrophils. J Biomed Sci. 2012;19:89.
[0518] 6. Wikoff WR, Anfora AT, Liu J, Schultz PG, Lesley SA, Peters EC, Siuzdak G. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc Natl Acad Sci U S A. 2009;106:3698-3703.
[0519] 7. Simoni RD, Hill RL, Vaughan M. Comparative studies of the mode of oxidation of phenyl derivatives of fatty acids by the animal organism and by hydrogen peroxide (Dakin, H. D. (1908) J. Biol. Chem. 4, 419-435). J Biol Chem. 2002;277:e4-5.
[0520] 8. Zhu Y, Dwidar M, Nemet I, Buffa JA, Sangwan N, Li XS, Anderson JT, Romano KA, Fu X, Funabashi M, et al. Two distinct gut microbial pathways contribute to meta- organismal production of phenylacetylglutamine with links to cardiovascular disease. Cell Host Microbe. 2023;31 :18-32 el9.
[0521] 9. Nandi DL, Lucas SV, Webster LT, Jr. Benzoyl-coenzyme A:glycine N- acyltransferase and phenylacetyl-coenzyme A:glycine N-acyltransferase from bovine liver mitochondria. Purification and characterization. J Biol Chem. 1979;254:7230-7237.
[0522] 10. Webster LT, Siddiqui UA, Lucas SV, Strong JM, Mieyal JJ. Identification of separate acyl- CoA:glycine and acyl-CoA:L-glutamine N-acyltransferase activities in mitochondrial fractions from liver of rhesus monkey and man. J Biol Chem. 1976;251:3352-3358.
[0523] 11. Needham BD, Funabashi M, Adame MD, Wang Z, Boktor JC, Haney J, Wu WL, Rabut C, Ladinsky MS, Hwang SJ, et al. A gut-derived metabolite alters brain activity and anxiety behaviour in mice. Nature. 2022;602:647-653.
[0524] 12. Dawson LF, Donahue EH, Cartman ST, Barton RH, Bundy J, McNerney R, Minton NP, Wren BW. The analysis of para-cresol production and tolerance in Clostridium difficile 027 and 012 strains. BMC Microbiol. 2011 ;11:86
[0525] 13. Williams BB, Van Benschoten AH, Cimermancic P, Donia MS, Zimmermann M, Taketani M, Ishihara A, Kashyap PC, Fraser JS, Fischbach MA. Discovery and characterization of gut microbiota decarboxylases that can produce the neurotransmitter tryptamine. Cell Host Microbe. 2014;16:495-503. doi: 10.1016 / j.chom.2014.09.001
[0526] 14. Sakurai T, Odamaki T, Xiao JZ. Production of Indole- 3 -Lactic Acid by Bifidobacterium Strains Isolated fromHuman Infants. Microorganisms. 2019;7.
[0527] 15. Dickert S, Pierik AJ, Buckel W. Molecular characterization of phenyllactate dehydratase and its initiator from Clostridium sporogenes. Mol Microbiol. 2002;44:49-60.
[0528] 16. Smith EA, Macfarlane GT. Formation of Phenolic and Indolic Compounds by Anaerobic Bacteria in the Human Large Intestine. Microb Ecol. 1997;33:180-188. 17. Mohammed N, Onodera R, Or-Rashid MM. Degradation of tryptophan and related indolic compounds by ruminal bacteria, protozoa and their mixture in vitro. Amino Acids.
[0529] 2003;24:73-80.
[0530] 18. Banoglu E, Jha GG, King RS. Hepatic microsomal metabolism of indole to indoxyl, a precursor of indoxyl sulfate. Eur J Drug Metab Pharmacokinet. 2001 ;26:235-240.
[0531] 19. Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, Crews DC, Doria A, Estrella MM, Froissart M, et al. New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. N Engl J Med. 2021 ;385: 1737-1749.
[0532] Although only a few exemplary embodiments have been described in detail, those skilled in the art will readily appreciate that many modifications are possible in the exemplary embodiments without materially departing from the novel teachings and advantages of this disclosure. Accordingly, all such modifications and alternative are intended to be included within the scope of the invention as defined in the following claims. Those skilled in the art should also realize that such modifications and equivalent constructions or methods do not depart from the spirit and scope of the present disclosure, and that they may make various changes, substitutions, and alterations herein without departing from the spirit and scope of the present disclosure.
Claims
CLAIMSWhat is claimed is:
1. A composition, kit, or system comprising: a) a sample from a subject having: a cardiovascular disease, or an elevated risk of cardiovascular disease, and / or elevated risk for a thrombotic event, or obesity, or an elevated risk or obesity, or a metabolic disorder, or an elevated risk of having a metabolic disorder, and b) a stable isotope labeled first and / or second gut derived aromatic amino acid metabolite (GDAAM), wherein said fist GDAAM is selected from the following first group: phenylacetyl glycine, Phenylacetic acid, Hippuric acid, Phenylacryl glycine, p-Cresol glucuronide, 4-OH-Phenyllactic acid, 4-Ethylphenylsulfate, 4-OH-Benzoic acid, 4-OH- Hippuric acid, 2-OH-Hippuric acid, 3-OH-Hippuric acid, Indole glucuronide, 5-OH-indole-3- acetic acid, Indole-3 -acetyl glutamine, Serotonin, Indole-3 -acetic acid, Indole-3 -lactic acid, and N-Acetyl-tryptophan, and wherein said second GDAAM is selected from the following second group: Tyrosine, 2-OH-Benzoic acid, and Tryptophan.
2. The composition, kit, or system of Claim 1, wherein said stable isotope is selected from "H,13C, and15N.
3. The composition, kit, or system of Claim 1, wherein said sample comprises a plasma sample or serum sample.
4. The composition, kit, or system of Claim 1, further comprising: c) un-labelled first and / or second GDAAM.
5. The composition, kit, or system of Claim 4, wherein said unlabeled first GDAAM is present in said in said sample that is increased compared to a first corresponding control value.
6. The composition, kit, or system of Claim 4, wherein said unlabeled second GDAAM is present in said sample at a decreased level compared to a second corresponding control value.
7. The composition, kit, or system of Claim 1, wherein said sample further comprises a stable isotope labeled third, fourth, fifth, sixth, seventh, or eighth GDAAM selected from the first and / or second group.
8. The composition, kit, or system of Claim 1, wherein said sample comprises at least one, or at least two, or at least three or at least four stable isotope labeled compounds: PAGln, TMAO, I3P, Hippuric acid, 4-OH-hippuric acid, 5-OH-indole-3-acetic acid, p-cresol glucuronide, pCS, IS, Tyr, Trp, Tndole-3-acetyl glutamine.
9. The composition of claim 1 , further comprising stable isotope labeled molecule selected from: TMAO (trimethylamine-N-oxide), trimethyllysine, Crotonobetaine, gamma butyrobetaine, carnitine, choline, and betaine.
10. A method of detecting the level of a first and / or second gut derived aromatic amino acid metabolite (GDAAM) in a sample from a subject comprising: a) obtaining a sample, wherein said sample is from a human subject with cardiovascular disease; and b) treating at least a portion of said sample under conditions such that said first and / or second GDAAM level present in said sample is determined.
11. The method of Claim 10, wherein said level of said first and / or second GDAAM in said sample is determined by mass spectrometry.
12. The method of Claim 10, wherein said sample is a plasma or serum sample.
13. The method of Claim 10, wherein said first GDAAM is selected from the following first group: phenylacetyl glycine, Phenylacetic acid, Hippuric acid, Phenylacryl glycine, p- Cresol glucuronide, 4-OH-Phenyllactic acid, 4-Ethylphenylsulfate, 4-OH-Benzoic acid, 4- OH-Hippuric acid, 2-OH-Hippuric acid, 3-OH-Hippuric acid, Indole glucuronide, 5-OH- indole-3-acetic acid, Indole- 3 -acetyl glutamine, Serotonin, Indole-3-acetic acid, Indole-3- lactic acid, and N-Acetyl-tryptophan, and wherein said second GDAAM is selected from the following second group: Tyrosine, 2-OH-Benzoic acid, Tryptophan, and Indole- 3 -propionic acid.
14. A method of treatment comprising: a) identifying a subject as having: i) increased levels of a first gut derived aromatic amino acid metabolite (GDAAM) compared to a first corresponding control value, and / or ii ) decreased levels of a second GDAAM compared to a second corresponding control value, wherein said first GDAAM is selected from the following first group: phenylacetyl glycine, Phenylacetic acid, Hippuric acid, Phenylacryl glycine, p-Cresol glucuronide, 4-OH-Phenyllactic acid, 4-Ethylphenylsulfate, 4-OH- Benzoic acid, 4- OH-Hippuric acid, 2-OH-Hippuric acid, 3-OH-Hippuric acid, Indole glucuronide, 5 -OH-indole-3 -acetic acid, Indole- 3 -acetyl glutamine, Serotonin, Indole- 3-acetic acid, Indole-3 -lactic acid, and N-Acetyl-tryptophan, and wherein said second GDAAM is selected from the following second group: Tyrosine, 2-OH-Benzoic acid, and Tryptophan; and B) treating said subject with: i) an agent or procedure that inhibits the TMA / FM03 / TMA0 pathway, and / or ii) a cardiovascular disease therapeutic, and / or iii) an anti-thrombotic agent, and / or iv) an anti-platelet agent, and / or v) an antibiotic or antimicrobial that reduces the production in the gut of said first GDAAM, and / or vi) providing or prescribing a diet with reduced levels of carnitine, choline, and / or lecithin containing compounds; and / or vii) an anti-obesity agent; and / or viii) an metabolic disease agent.
15. The method of Claim 14, wherein said subject is a human, and / or wherein said identifying comprises receiving information regarding said subject as having: i) increased levels of a first GDAAM compared to a first corresponding control value, and / or ii) decreased levels of a second GDAAM compared to a second corresponding control value, and optionally wherein said receiving information comprises receiving a report, wherein said receiving said report is optionally via: 1) the mail system, 2) email, or 3) via a LAN of a hospital or clinic.
16. The method of Claim 14, wherein said identifying comprises identifying both said increased level of said first GDAAM, and a decreased level of said second GDAAM.
17. The method of Claim 16, wherein said first GDAAM is phenylacetyl glutamine (PAGln) and said second GDAAM is Indole-3 -propionic acid (I3P).
18. The method of Claim 14, further comprising: identifying an additional GDAAM as having: i) an increased level compared to a first additional control value when selected from said first group, or ii) having a decreased level compared to a second additional control value when selected from said second group.
19. The method of Claim 18, wherein: i) said first GDAAM is PAGln, and said additional GDAAM is I3P; ii) said first GDAAM is PAGln, and said additional GDAAM is Trp; or iii) said first GDAAM is PAGln, and said additional GDAAM is Tyr.
20. The method of Claim 18, wherein: i) said first GDAAM is 4-OH-HA, and said additional GDAAM is I3P; ii) said first GDAAM is 4-OH-HA, and said additional GDAAM is Trp; or iii) said first GDAAM is 4-OH-HA, and said additional GDAAM is Tyr.
21. The method of Claim 18, further comprising identifying further comprises identifying an increased level in a particular marker compared to a corresponding particular control value, wherein said particular marker is selected from: TMAO (trimethylamine-N-oxide), trimethyllysine, Crotonobetaine, gamma butyrobetaine, carnitine, choline, and betaine.
22. The method of Claim 21 , wherein said subject has, or is suspected of having, a cardiovascular disease.
23. The method of Claim 22, wherein said cardiovascular disease is selected from: coronary artery disease (CAD), peripheral artery disease (PAD), heart failure (HF), HF with preserved ejection fraction (HFpEF), HF with reduced ejection fraction (HFrEF), left ventricular systolic dysfunction, need for revascularization, need for CABG, need for angioplasty, need for stent, vascular aneurysm, abdominal aortic aneurysm, thoracic aorticaneurysm, arrhythmia, atrial fibrillation, ventricular fibrillation, ventricular tachycardia, acute coronary syndrome, NSTIMI and STIMI.
24. The method of Claim 14, wherein said subject is, or is suspected of being, at risk for a thrombotic event.
25. The method of Claim 21 , further comprising: identifying an additional GDAAM as having: i) an increased level compared to a first additional control value if selected from said first group, or ii) having a decreased level compared to a second additional control value if selected from said second group.
26. The method of Claim 14, wherein said first and second corresponding control values are derived from samples from the general public or from a group known to not have cardiovascular disease or be at elevated risk for a thrombotic event.
27. The method of Claim 14, wherein said cardiovascular disease therapeutic is a lipid lowering agent, and optionally wherein said lipid lowering agent comprising a statin.
28. The method of Claim 27, wherein said cardiovascular disease therapeutic is selected from: i) atorvastatin, rosuvastatin, simvastatin, pravastatin, lovastatin, pitavastatin, bempadoic acid, ii) a PCSK9 inhibitor, wherein said PCSK9 inhibitor optionally comprises a anti-PCSK9 antisense or siRNA, or an anti-PCSK9 antibody, fragment thereof, or nanobody, iii) an apoB inhibitor, wherein said apoB inhibitor optionally comprises a anti-apoB antisense or siRNA, or an anti-apoB antibody, fragment thereof, or nanobody; or iv) lipoprotein a or apolipoprotein a.
29. The method of Claim 14, wherein said sample is selected from the group consisting of: a plasma sample, a serum sample, and a urine sample.
30. The method of Claim 14, wherein said agent or procedure that inhibits the TMA / FM03 / TMA0 pathway is selected from the group consisting of: i) a compound selected from CC136 and CC272; ii) acetylsalicylic acid with or without an enteric coating; iii) an acetylsalicylic acid derivative with or without an enteric coating; iv) compound CC270;v) a gut TMA lyase inhibitor; vi) fecal microbiota transplantation and / or synthetic polymicrobial feces transplantation, and / or gut bacteria spores; vii) delivery of acetylsalicylic acid or derivative thereof directly to the colon or cecum of said subject; viii) a probiotic or prebiotic that reduces production in the gut of said first GDAAM; ix) a TMA and / or TMAO sequestering agent; x) a TMA lyase inhibitor is selected from: a halomethyl choline, iodomethylcholine, fluoromethycholine, a halomethyl betaine, a halomethyl betaine salt, a halomethyl betaine amide, and a halomethyl dimethyl amino alcohol; xi) 3-(2,2,2-trimethylhydraziniumyl) propionate; and xii) a compound of any of Formulas I-III or V.
31. The method of Claim 14, wherein said cardiovascular disease therapeutic, anti-obesity agent, and / or anti-metabolic disease agent is selected from: an ACE inhibitor, an angiotensin II receptor blocker (ARB), insulin, an amylinomimetic drug, an alpha-glucosidase inhibitor, a biguanide, a dopamine agonist, a DPP-4 inhibitor, a glucagon- like peptide, a meglitinide, a sodium glucose transporter (SGLT) 2 inhibitor, a sulfonylureas, Pioglitazone, cenicriviroc, Elafibranor, Ocaliva (obeticholic acid), Selonsertib, thiazolidinedione, Inclisirin, anti-apoB targeting drugs, Anti-LPa targeting drugs, anti ATP citrate lyase targeting (bempedoic acid) drugs, SGLT2 inhibitor, SGLT1 inhibitor, SGLT1 / 2 mixed inhibitors, and / or GLP1 agonists.
32. The method of Claim 14, wherein said antibiotic is at least one antibiotic selected from the group consisting of: metronidazole, ciprofloxacin, neomycin, amoxicillin, and a broad spectrum antibiotic; and wherein said subject does not have an active infection.
33. A method of performing an activity based on a level of a first and / or a second gut derived aromatic amino acid metabolite (GDAAM) in a sample from a subject comprising: a) determining, or receiving information regarding, the level of said first and / or second GDAAM in a sample from a subject, wherein said first GDAAM is selected from the following first group: phenylacetyl glycine, Phenylacetic acid, Hippuric acid, Phenylacryl glycine, p-Cresol glucuronide, 4-OH- Phenyllactic acid, 4-Ethylphenylsulfate, 4-OH-Benzoic acid, 4-OH-Hippuric acid, 2-OH- Hippuric acid, 3-OH-Hippuric acid, Indole glucuronide, 5-OH-indole-3-acetic acid, Indole-3-acetyl glutamine, Serotonin, Indole-3 -acetic acid, Indole-3 -lactic acid, and N-Acetyl- tryptophan, and wherein said second GDAAM is selected from the following second group: Tyrosine (Tyr), 2-OH-Benzoic acid, and Tryptophan (Trp); and b) identifying an increased level of said first GDAAM in said sample compared to a first corresponding control value and / or identifying a decreased level of said second GDAAM in said sample compared to a second corresponding control value, and performing at least one of the following activities: i) treating said subject with: A) an agent or procedure that inhibits the TMA / FM03 / TMA0 pathway, and / or B) a cardiovascular disease therapeutic, and / or C) an anti-thrombotic agent, and / or D) an anti-platelet agent, and / or E) an antibiotic or antimicrobial that reduces trimethylamine (TMA) production in the gut, and / or F) providing or prescribing a dietary intervention; ii ) generating and / or transmitting a report that: A) displays said first and / or said second GDAAM level, and B) indicates that said subject is in need of said agent or procedure that inhibits the TMA / FM03 / TMA0 pathway, and / or said cardiovascular disease agent, and / or said anti-thrombotic agent, and / or said antiplatelet agent, and / or said antibiotic or antimicrobial agent, anti-obesity agent, anti- metabolic disease agent, and / or said diet; and iii) characterizing said subject as having a cardiovascular disease, or an elevated risk for cardiovascular disease, or an elevated risk for obesity, or an elevated risk for a metabolic disease, and / or elevated risk for a thrombotic event.
34. The method of Claim 33, wherein said identifying comprises identifying both said increased level of said first GDAAM, and a decreased level of said second GDAAM.
35. The method of Claim 34, wherein said first GDAAM is phenylacetyl glutamine (PAGln) and said second GDAAM is Indole-3 -propionic acid (I3P).
36. The method of Claim 33, further comprising: determining the level of an additional GDAAM that is different from said first or second GDAAM, wherein said additional marker is phenylacetyl glutamine or Indole-3 -propionic acid, or is selected from said first group or said second group, but does not include p-Cresol sulfate or Indoxyl sulfate.
37. The method of Claim 36, wherein said identifying comprises identifying said increased level of said first GDAAM, or said decreased level of said second GDAAM, and further identifying said additional GDAAM as having: i) an increased level compared to a first additional control value if selected from said first group, or ii) having a decreased level compared to a second additional control value if selected from said second group.
38. The method of Claim 37, wherein: i) said first GDAAM is PAGln, and said additional GDAAM is I3P; ii) said first GDAAM is PAGln, and said additional GDAAM is Trp; iii) said first GDAAM is PAGln, and said additional GDAAM is Tyr; iv) said first GDAAM is 4-OH-HA, and said additional GDAAM is I3P; v) said first GDAAM is 4-OH-HA, and said additional GDAAM is Trp; or vi) said first GDAAM is 4-OH-HA, and said additional GDAAM is Tyr.
39. The method of Claim 33, wherein said identifying an increased level of said first GDAAM in said sample comprises identifying said level of said first GDAAM as at, or above, the 75% quartile range; and / or wherein said identifying a decreased level of said second GDAAM in said sample comprises identifying said level of said second GDAAM as at or below the 25% quartile range.
40. The method of Claim 37, further comprising detecting the level of a particular marker selected from: TMAO (trimethylamine-N-oxide), trimethyllysine, Crotonobetaine, gamma butyrobetaine, carnitine, choline, and betaine.
41. The method of Claim 40, wherein said identifying further comprises identifying an increased level in said particular marker compared to a corresponding particular control value.
42. The method of Claim 33, wherein said subject has, or is suspected of having, a cardiovascular disease.
43. The method of Claim 42, wherein said cardiovascular disease is selected from: coronary artery disease (CAD), peripheral artery disease (PAD), heart failure (HF), HF with preserved ejection fraction (HFpEF), HF with reduced ejection fraction (HFrEF), left ventricular systolic dysfunction, need for revascularization, need for CABG, need forangioplasty, need for stent, vascular aneurysm, abdominal aortic aneurysm, thoracic aortic aneurysm, arrhythmia, atrial fibrillation, ventricular fibrillation, ventricular tachycardia, acute coronary syndrome, NSTEMI and STEMI Stroke, transient ischemic attack (TIA), cardiovascular disease (CVD).
44. The method of Claim 33, wherein said subject is, or is suspected of being, at risk for a thrombotic event.
45. The method of Claim 36, further comprising: determining the level of a further GDAAM that is different from said first or second GDAAM and different from said additional marker, wherein said further marker is phenylacetyl glutamine or p-Cresol sulfate, Indoxyl sulfate, or Indole- 3 -propionic acid, or is selected from said first group or said second group.
46. The method of Claim 36, wherein said identifying comprises:A) identifying said increased level of said first GDAAM, or said decreased level of said second GDAAM,B) identifying said additional GDAAM as having: i) an increased level compared to a first additional control value if selected from said first group, or ii) having a decreased level compared to a second additional control value if selected from said second group, andC) identifying said further marker as having: i) an increased level compared to a first further control value if selected from said first group, or ii) having a decreased level compared to a second further control value if selected from said second group.
47. The method of Claim 46, further comprising detecting the level of a particular marker selected from: TMAO (trimethylamine-N-oxide), trimethyllysine, Crotonobetaine, gamma butyrobetaine, carnitine, choline, and betaine.
48. The method of Claim 47, wherein said identifying further comprises identifying an increased level in said particular marker compared to a corresponding particular control value.
49. The method of Claim 33, wherein said report further displays said corresponding control value for said first and / or second GDAAM.
50. The method of Claim 33, wherein said report comprises a paper report or an electronic report; and / or wherein said receiving information comprises receiving said report, wherein said receiving said report is optionally via: 1) the mail system, 2) email, or 3) via a LAN of a hospital or clinic.
51. The method of Claim 33, wherein said transmitting said report comprises: 1) mailing the reporting through the mail system, 2) emailing the report over the internet, or 3) sending the report through a local area network (LAN) or a hospital or clinic.
52. The method of Claim 33, wherein said first and second corresponding control values are derived from samples from the general public or from a group known to not have cardiovascular disease or be at elevated risk for a thrombotic event.
53. The method of Claim 33, wherein said cardiovascular disease therapeutic is a Lipid lowering agent, and optionally wherein said lipid lowering agent comprises a statin.
54. The method of Claim 33, wherein said cardiovascular disease therapeutic is selected from: i) atorvastatin, rosuvastatin, simvastatin, pravastatin, lovastatin, pitavastatin, bempadoic acid, ii) a PCSK9 inhibitor, wherein said PCSK9 inhibitor optionally comprises a anti-PCSK9 antisense or siRNA, or an anti-PCSK9 antibody, fragment thereof, or nanobody, iii) an apoB inhibitor, wherein said apoB inhibitor optionally comprises a anti-apoB antisense or siRNA, or an anti-apoB antibody, fragment thereof, or nanobody; or iv) lipoprotein a or apolipoprotein a.
55. The method of Claim 33, wherein said sample is selected from the group consisting of: a plasma sample, a serum sample, and a urine sample.
56. The method of Claim 33, wherein said determining comprises detecting said GDAAM with an analytical device selected from: a mass spectrometer, NMR spectrometer, and a UV / Vis spectrometer.
57. The method of Claim 33, wherein said agent or procedure that inhibits the TMA / FM03 / TMA0 pathway is selected from the group consisting of: i) a compound selected from CC136 and CC272; ii) acetylsalicylic acid with or without an enteric coating;iii) an acetylsalicylic acid derivative with or without an enteric coating; iv) compound CC270; v) a gut TMA lyase inhibitor; vi) fecal microbiota transplantation and / or synthetic polymicrobial feces transplantation, and / or gut bacteria spores; vii) delivery of acetylsalicylic acid or derivative thereof directly to the colon or cecum of said subject; viii) a probiotic or prebiotic that reduces production in the gut of said first GDAAM; ix) a TMA and / or TMAO sequestering agent; x) a TMA lyase inhibitor is selected from: a halomethyl choline, iodomethylcholine, fluoromethycholine, a halomethyl betaine, a halomethyl betaine salt, a halomethyl betaine amide, and a halomethyl dimethyl amino alcohol; xi) 3-(2,2,2-trimethylhydraziniumyl) propionate; and xii) a compound of any of Formulas I-III or V.
58. The method of Claim 33, wherein said cardiovascular disease therapeutic, anti-obesity agent, and / or anti-metabolic disease agent is selected from: an ACE inhibitor, an angiotensin II receptor blocker (ARB), insulin, an amylinomimetic drug, an alpha-glucosidase inhibitor, a biguanide, a dopamine agonist, a DPP-4 inhibitor, a glucagon- like peptide, a meglitinide, a sodium glucose transporter (SGLT) 2 inhibitor, a sulfonylureas, Pioglitazone, cenicriviroc, Elafibranor, Ocaliva (obeticholic acid), Selonsertib, thiazolidinedione, Inclisirin, anti-apoB targeting drugs, Anti-LPa targeting drugs, anti ATP citrate lyase targeting (bempedoic acid) drugs, SGLT2 inhibitor, SGLT1 inhibitor, SGLT1 / 2 mixed inhibitors, and / or GLP1 agonists, a Beta Blocker, statin, PCSK9 inhibitor, ATP-citrate lyase inhibitor (bempedoic acid), SGLT2 inhibitors, GLP1 agonists, metformin, SGLT1 inhibitors, and mixed SGLT1 / 2 inhibitors, inclisirin and ASO or siRNA to apoB.
59. The method of Claim 33, wherein said antibiotic is at least one antibiotic selected from the group consisting of: metronidazole, ciprofloxacin, neomycin, amoxicillin, and a broad spectrum antibiotic; and wherein said subject does not have an active infection.
60. A system or kit comprising: a) a report for a subject with cardiovascular disease, wherein said report indicates that said patient has: i) increased levels of a first gut derived aromatic amino acid metabolite (GDAAM) compared to a first corresponding control value, and / or ii ) decreased levels of a second gut derived aromatic amino acid metabolite (GDAAM) compared to a second corresponding control value, wherein said first GDAAM is selected from the following first group: phenylacetyl glycine, Phenylacetic acid, Hippuric acid, Phenylacryl glycine, p-Cresol glucuronide, 4-OH-Phenyllactic acid, 4-Ethylphenylsulfate, 4-OH- Benzoic acid, 4- OH-Hippuric acid, 2-OH-Hippuric acid, 3-OH-Hippuric acid, Indole glucuronide, 5- OH-indole-3-acetic acid, Indole-3 -acetyl glutamine, Serotonin, Indole-3-acetic acid, Indole-3-lactic acid, and N-Acetyl-tryptophan, and wherein said second GDAAM is selected from the following second group: Tyrosine, 2-OH-Benzoic acid, and Tryptophan; and N6-trimethyl-lysine; and b) at least one of the following: i) an agent that inhibits the TMA / FM03 / TMA0 pathway; ii) a cardiovascular disease therapeutic, and iii) an anti-thrombotic agent, iv) an anti-platelet agent, and v) an antibiotic or antimicrobial that reduces trimethylamine (TMA) production in the gut.
61. The system of Claim 60, wherein said first agent that inhibits the TMA / FMO3 / TMAO pathway is selected from the group consisting of: i) a compound selected from CC136 and CC272; ii) acetylsalicylic acid with or without an enteric coating; iii) an acetylsalicylic acid derivative with or without an enteric coating; iv) compound CC270; v) a gut TMA lyase inhibitor; vi) fecal microbiota transplantation and / or synthetic polymicrobial feces transplantation, and / or gut bacteria spores; vii) delivery of acetylsalicylic acid or derivative thereof directly to the colon or cecum of said subject;viii) a probiotic or prebiotic that reduces production in the gut of said first GDAAM; ix) a TMA and / or TMAO sequestering agent; x) a TMA lyase inhibitor is selected from: a halomethyl choline, iodomethylcholine, fluoromethycholine, a halomethyl betaine, a halomethyl betaine salt, a halomethyl betaine amide, and a halomethyl dimethyl amino alcohol; xi) 3-(2,2,2-trimethylhydraziniumyl) propionate; and xii) a compound of any of Formulas I-TIT or V.
62. The system of Claim 61, wherein said FM03 inhibitor comprises Tenofovir or Methimazole.
63. The system of Claim 61, wherein said antiplatelet agent is selected from the group consisting of: abciximab, dipyridamole / ASA, anagrelide, cilostazol, clopidogrel, dipyridamole, eptifabatide, prasugrel, ticagrelor, ticlopidine, tirofiban, and vorapaxar.
